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SYNOPSIS 
 
 
 
 
Synopsis…..1
“STUDIES ON SOME HETEROCYCLIC
ENTITIES OF MEDICINAL INTEREST”
A brief summary of the work to be incorporated in the thesis entitled,
“STUDIES ON SOME HETEROCYCLIC ENTITIES OF MEDICINAL INTEREST”
has been summarized as under.
A. Studies on imidazo pyridine derivatives
The aza-indolizine contains a phenyl ring fused to a imidazole ring as
indicated in the structure, hence it is also known as imidazo[1,2-a]pyridine.The
constitution of imidazo[1,2-a]pyridine was represented by W.L.Mosby.
N
N
1
2
3
5
4
6
7
8
9
The group of compound containing imidazo[1,2-a]pyridine moiety are
prominent structural feature in a variety of natural products as well as in other
compounds of medicinal interest and have attracted attention for their biological
activities.
PART-I : SYNTHESIS OF (2Z)-3-[2-(4-CHLOROPHENYL)-8-METHYL IMIDAZO
[1,2-a]PYRIDINE-3-YL]-1-ARYL PROP-2-EN-1-ONE.
Chalcone derivatives have been found to be associated with various
pharmacological activities. These finding encouraged as to synthesize some new
novel synthesis.
Synopsis…..2
N
N
Cl
CH3
R
O
Where,
R= Aryl
(2Z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-
en-1-one derivatives prepared by the condensation of 2-(4-chlorophenyl)-6-methyl
imidazo[1,2-a]pyridine-3-carbaldehyde with various substituted ketone in methanol.
PART-II : SYNTHESIS OF 6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-IMIDAZO
[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-ONE.
Pyrimidine derivatives have been reported to possess various
pharmacological activities like antibacterial, antifungal, insecticide etc. In order to
achive better potency, we have synthesized pyrimidine derivatives.
Where,
R= Aryl
N
N
Cl
CH3
NH
N
R
X X = O,S,NH
Synopsis…..3
Pyrimidine derivatives have been prepared by the reaction of (2Z)-3-
[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one and
Urea/Thiourea/Guanidine in basic media and methanol as a solvents.
PART-III : SYNTHESIS OF ETHYL-6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL-2-OXOCYCLOHEX-3-ENE-
CARBOXYLATE.
Cyclohexenone derivatives have been reported to possess various
Pharmacological activities like antibacterial, antifungal etc. In order to achieve better
potency, we have synthesized Cyclohexenone derivatives.
Where,
R= Aryl
N
N
Cl
CH3
O
R
COOR1
R1 = Methyl,Ethyl,t-Butyl
Cyclohexenone derivatives have been prepared by the reaction of (2Z)-3-
[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one and
Methylacetoacetate/Ethylacetoacetate/t-Butylacetoacetate with Na2CO3 in acetone
as solvent.
PART-IV : SYNTHESIS OF 2-(4-CHLOROPHENYL)-3-(4,5-DIHYDRO-3-ARYL-
1H-PYRAZOL-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Pyrazoline derivatives are endowed with various antimicrobial activities.
Synopsis…..4
Looking at their versatile therapeutic importance and with an aim to getting better
drug. It was considered worthwhile to synthesized some new pyrazoline.
Where,
R=Aryl
N
N
Cl
CH3
N
NH
R
The preparation of 2-(4-chlorophenyl)-3-(4,5-dihydro-3-aryl-1H-pyrazol-5-yl)-
8-methyl-1H-imidazo[1,2-a]pyridine derivatives has been undertaken by the cyclo-
condensation of chalcone with hydrazine hydrate and glacial acetic acid.
PART-V : SYNTHESIS OF 2-(4-CHLOROPHENYL)-3-(3-ARYL ISOXAZOLE-5-
YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Isoxazole have been found to be associated with broad spectrum of biological
activities like antibacterial, antifungal, insecticidal, anesthetic, analgesic and
antidaibetic.
N
N
Cl
CH3
O
N R
Where,
R=Aryl
Synopsis…..5
Isoxazole derivative synthesized by the reaction of (2Z)-3-[2-(4-chloro
phenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one and hydroxyl
amine hydrochloride in ethanol containing sodium hydroxide was refluxed for 11hrs,
the product was isolated by pouring the alcoholic solution on to crushed ice, then
filtered, dried it.
PART-VI : SYNTHESIS OF (3-(2-(4-CHLOROPHENYL)-8-METHYL-1H- IMIDAZO
[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL) ARYL METHANONE.
Oxirane derivatives have been reported to possess various pharmacological
activities like antibacterial, antifungal etc. In order to achive better potency, we have
synthesized oxirane derivatives.
N
N
Cl
CH3
R
O
O
R=Aryl
Where,
Oxirane or Epoxide derivatives synthesized by the reaction of (2Z)-3-[2-(4-
chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-arylprop-2-en-1-one in mixture
of acetone and methanol with 8% aqueous sodium hydroxide followed by addition
of 30% hydrogen peroxide, the solution was shaken and heated to the boiling point
for 1h, then allowed to stand overnight at room temperature, then water was added
in the solution was extracted with ether. The ether layer was evaporated to give
Epoxide derivative compound.
Synopsis…..6
The reaction monitoring of the all compounds done by thin layer
chromatography using two different solvent systems (Rf1 & Rf2).The constitution of
newly synthesized compounds have been delineated by elemental analysis,
FT-IR, 1H NMR and Mass spectroscopy.
The compounds have been screened for their in vitro therapeutic assay like
antibacterial activities towards Gram positive and Gram negative bacterial strain
and antifungal activity towards fungal strain at different concentration (Minimum
Inhibitory Concentration).The biological activities of synthesized compounds have
been compared with standard drugs at different concentrations.
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GENERAL INTRODUCTION 
 
(A) Drug 
 
The word drug is derived from the French word “drogue” which means „a dry 
herb‟. It is the single active chemical entity present in a medicine that is used for 
diagnosis, prevention, treatment/cure of a disease. This disease oriented definition 
of drug does not include contraceptives or use of drugs for improvement of health. 
According to “WHO” a drug may be defined as “Any substance or product which is 
used or intended to be used for modifying or exploring physiological system as 
pathological status for the benefit of the recipient”. 
 
(B) Pharmacology 
 
Pharmacology is the science of drugs. In a broad sense, it deals with 
interaction of exogenously administered chemical molecules (drugs) with living 
system. It encompasses all aspects of knowledge about drugs, but most importantly 
those that are relevant to effective and safe use for medicinal purposes. For 
thousands of years most drugs were crude natural products of unknown composition 
and limited efficiency. Only the over effects of these substances on the body were 
rather imprecisely known, but how the same were produced was entirely unknown. 
Over the past 100 years or so, drugs have been purified, chemically characterized 
and a vast variety of highly potent and selective new drugs has been developed. 
The two main divisions of pharmacology are pharmacodynamics and pharmaco 
kinetics. 
 
(a) Pharmacodynamics: It is derived from the Greek word “dynamic” means 
Power. What the drug does to the body ? This includes physiological and 
biochemical effects of drugs and their mechanism of action at macromolecular 
/ sub cellular organ systems. 
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(b) Pharmacokinetics: It is derived from the Greek word „Kinesis‟ means 
movement. What the body does to the drug? This refers to movements of the drug 
in and alternation of the drug by the body; includes absorption, distribution, binding / 
localization / storage, biotransformation and excretion of the drug.  
 
Some other important aspects of pharmacology are given as under : 
 
 Pharmacotherapeutics : It is the application of pharmacodynamics 
information together with knowledge of the disease for its prevention, 
mitigation or cure. 
 
 Clinical Pharmacology: It is the scientific study of drug in man. It includes 
Pharmacodynamics and pharmacokinetic investigation in healthy volunteers 
and in patients; evaluation of efficiency and safety of drugs and comparative 
trials with other forms of treatments; surveillance of patterns of drug uses, 
adverse effects, etc. 
 
 Chemotherapy : It is the treatment of systemic infection/malignancy with 
specific drugs that have selective toxicity for the infecting organism/malignant 
cell with less effect on the host cells. 
 
Drugs in general, can thus be divided into : 
 Pharmacodynamic agents : These are chemical substances designed to 
have pharmacodynamics effect in the recipient. 
 Chemotherapeutic agents : These are chemical substances designed for 
the treatment of infectious diseases or by the proliferation of malignant cells. 
 
(c) Essential Drug Concept : The „WHO‟ has defined Essential Drugs as “those 
that satisfy the healthcare needs of majority of the population; they should therefore 
be available at all times in adequate amounts and in appropriate dosage form”. It  
General Introduction ….. 9 
 
has been realized that only a handful of drugs out of the multitude available can 
meet the health needs of majority of the people in any country, and that may be well 
tested and cheaper drugs are equally (or more) efficient and safe as their newer 
more expensive congeners. For optimum utilization of resources, governments 
(specially in developing countries) should concentrate on these drugs by identifying 
them as Essential Drugs. The “WHO” has laid down criteria guide 
 
Selection of an essential drug: 
 
(I) Adequate data on its efficiency and safety should be available from clinical                   
studies. 
(II) It should be available in a form in which quality, including bioavailability, and 
stability on storage can be assured. 
(III) Its choice should depend upon pattern of prevalent diseases; availability of    
facilities and trained personnel; financial resources; genetic, demographic 
and environmental factors. 
(IV) In case of two or more similar drugs, choice should be made on the basis of 
their relative efficiency, safety, quality, price, availability and cost benefit ratio 
should be a major consideration. 
(V) Choice may also be influenced by comparative pharmacokinetic properties 
and local facilities for manufacture and storage. 
(VI) Most essential drug should be single compound. Fixed ratio combination 
products should be included only when dosage of each ingredient meets the 
requirements of a defined population group, and when the combination has a 
proven advantage. 
(VII) Selection of essential drug should be a continuous process which should take 
into account the changing priorities for public health action, epidemiological 
condition as well as availability of better drugs/ formulations and progress in 
pharmacological knowledge. 
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(C) Drug Development 
 
Many natural products by trial and error, came into practice for combating 
Human ailments existent during early human observation. With the advent of 
modern scientific approach, various plant medicines came under chemical scrutiny, 
ultimately leading to the isolation of active principles since early. 
 
               Such compounds either in extract form or in pure form became a part of 
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use for 
over 5000 years for the treatment of various types of fever and respiratory ailments, 
its active principle, Ephedrine was isolated in 1887. In 1925 chemical investigations 
followed by pharmacological evaluation led this compound into the modern 
medicine. Similarly during this period, urea stibamine was introduced as the first 
drug in 1920 for the treatment of Kala-azar. In 1930, De Rauwolfia preparations 
were first employed for sedative and hypotensive properties. 
  
A drug is a substance having abnormal effect on certain body functions eg. 
Strychnine stimulates the action of heart and aspirin retards its action. Since both of 
them effects abnormally, the two substances are known as drugs. Chemical 
sciences contributed extensively new discoveries leading to useful drugs since after 
1930.  
 
The modern concept of drug discovery started in 1933 by Gerhand Domagk 
with his finding of “Prontosil Red”, a compound responsible for the antibacterial 
activity. The advent of sulphonamides drew the attention for the different activities 
of various chemicals for bacterial and human cells, this important factor prompted 
Florey and Chain in 1939 to investigate penicillin which was discovered ten years 
earlier by Alexander Fleming. The spectacular chemotherapeutical properties of 
penicillin and its dramatic war-time development for the treatment of wounds made 
penicillin, a most commonly used inexpensive drug.  
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A large number of important drugs have been introduced during the period of 
1940 to 1980. This period is known as “Golden period” of new drug discovery.   
Thus starting from 1933 - the first antibacterial drug prontosil leading to         
various sulpha drugs ; 1940 - penicillin ; 1945 - chloroquine - antimalarial ; 1950 
Methyldopa - anti-hypertensive; 1967 - chlorothiazine - diuretic ; 1958 adrenergic 
beta blockers coronary vasodilatory; 1960 - semi synthetic penicillin-antibacterial ; 
1965 – trimethoprim - antimicrobial ;1967 disodium chromoglycoate -antiallergic; 
1972 - cimetidine H2 -antagonist; 1975 - verapamil - calciumantagonist and 1981 - 
captopril - antihypertensive. There are some specific examples representing new 
therapeuticagent  eg. Metormine, glipizide antidiabetic. 
 
(D) Latest Drug Developments 
 
The current interest in the creation of large, searchable libraries of organic 
compounds has captured the imagination of organic chemists and the drug 
discovery community. In numerous laboratories the Efforts are focused on the 
introduction of chemical diversity, which have been recently reviewed and 
pharmacologically interesting compounds have been identified from libraries of 
widely different compositions. 
 
Today, the chief source of agents for the cure, the mitigation or the 
prevention of diseases are the organic compounds, natural or synthetic, together 
with so called organometallics. Such agents have their origin in a number of ways 
(a) from naturally occurring materials of both plant and animal origin, and (b) from 
the isolation of organic compounds synthesized in laboratory whose structures are 
closely related to those of naturally occurring compounds for eg.atropine, steroids, 
morphine, cocaine etc. that have been known to possess useful medicinal 
properties. 
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The process of drug design is extensively driven by the instinct and 
experience of pharmaceutical research scientists. It is often instructive to attempt to  
“capture” these experiences by analyzing the historical record that are successful 
drug design projects of the past. From this analysis, the inferences are drawn which  
play an important role in shaping our current and future projects. Towards this 
region, we would like to analyse the structures of a large number of drugs – the 
ultimate product of a successful drug design effort. Our goal for this is to begin to 
deconvolute this information in order to apply it to design of new drugs. 
 
Different kinds of drugs are developed for different types of diseases viz. 
which can be defined with their names of the modern drugs are as under. 
 
(a) Anticancer drugs 
The drugs, which stop the abnormal growth of cell tissues in human body, are 
termed as anticancer drug. Vinblastin and Busulphan are the novel anticancer 
drugs. 
 
(b) Hepatoprotective drugs 
 Drug, which gives vitality to liver and protects liver by giving immunity power 
against antibodies, are termed as Hepatoprotective drug. 
 
(c) Antimalarial drugs 
 Drug, which kills the plasmodium causing malaria are called antimalarial 
drug. Combination of Sulphamethoxazole with Pyrimethamine is a novel 
antimalarial drug. 
 
(d) Drug for meningitis 
Drugs, which cures the inflammation of meningitis, are termed as meningitis 
drugs Cifalexin is a novel meningitis drug. 
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(e) Drug for typhoid 
Drugs, which kills the bacteria of Salmonella typhi causing typhoid, are known 
as typhoid drugs. A novel drug for typhoid is Ciprofloxacin. 
 
(f) Antidiabetic drugs 
Drugs, which converts the excess glucose of blood into glycogen are termed 
as antidiabetic drugs. Novel antidiabetic drugs are Metformin and Glipizide.  
 
(g) Antitubercular drugs 
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures 
lesions of pleural cavity. An antitubercular drug is Ethambutol. 
 
(h) Antiasthamatic drugs 
Drugs, which prevents the attack of asthama and gives relax respiration     
are called antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline, 
Theophylline and Asmon. 
 
(i) Antihypertensive drugs 
Drugs, which normalizes the blood pressure by dilating blood vessels         
are called antihypertensive drugs. Novel antihypertensive drugs are Atenolol, 
Amlodipine and Nifedipine. 
 
(j) Anti-AIDS drugs 
Drugs, which kills the viruses of AIDS  i.e., HIV-1 and HIV-2 are called anti-
AIDS  drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine. 
 
(k) Antacid drugs 
Drugs, which neutralize the acid in stomach and stops excessive secretion of 
acid, are called antacid drugs. Novel antacid drugs are Omeprazole and 
Lansoprazole. 
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(l) Non steroidal anti-inflammatory drugs (NSAID) 
Drugs, which gives relief from fever, pain and inflammation are called NSAID. 
Novel NSAID are Pyroxicam, Meloxicam and Nimesulide. 
 
 Different kind of drugs generally used are designed as anesthetic,antiviral, 
antibacterials,antifungal,antianxiety,antiinflammatory,analgesic,antipyretic,antiulcer 
and hypnotics which prompted us to synthesis drugs having Imidazo[1,2-a]pyridine 
moieties as a better therapeutic activity. 
 
AIMS & OBJECTIVES 
 
Aims and objectives of the present investigation are: 
(a) To generate several Chalcone,Pyrimidine,Isoxazole,Pyrazoline,Cyclohexinone, 
Oxirane derivatives bearing Imidazo[1,2-a]pyridine moiety. 
(b)    To characterize these products for their structural assignment using various 
Spectroscopic techniques like IR, 1H NMR and Mass spectroscopy. 
(c)  To screen these new derivatives for their antimicrobial activity using different 
Strains of bacteria and fungi and to compare antimicrobial activity with different 
known drugs at different concentrations for their MIC values. 
 
In view of these facts, the research work presented in thesis are as follows. 
 
STUDIES ON IMIDAZO[1,2-a]PYRIDINE 
 
Part-I   : STUDIES ON CHALCONES 
Part-II  : STUDIES ON PYRIMIDINES 
Part-III : STUDIES ON CYCLOHEXINONES 
Part-IV : STUDIES ON PYRAZOLINES 
Part-V  : STUDIES ON ISOXAZOLES 
Part-IV : STUDIES ON OXIRANES 
  
 
 
 
 
 
 
 
 
STUDIES ON IMIDAZO     
[1,2-a]PYRIDINE 
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INTRODUCTION 
 
The aza-indolizine contains a phenyl ring fused to a imidazole ring as 
indicated in the structure, hence it is also known as imidazo[1,2-a]pyridine.1 The 
constitution of imidazo[1,2-a]pyridine was represented by W.L.Mosby.2 
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 The group of compound containing imidazo[1,2-a]pyridine moiety are 
prominent structural feature in a variety of natural products as well as in other 
compounds of medicinal interest and have attracted attention for their biological 
activities. 
 
SYNTHETIC ASPECT  
Classical approaches of imidazo[1,2-a]pyridine involving different type of 
reaction has been described as under: 
 
(i) Reaction of (arylacetyl) imidazoles with acetylnedicarboxylic esters.3 
(ii) Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent 
elimination of nitrogen.4 
(iii) Cyclizations of 1-(2-alkynyl)-2-aminomethylimidazoles,which are obtained 
from substituted via six steps.5 
(iv) Coupling reaction of 2-aminopyridines with α-halo carbonyl compounds.6,7  
(v) Condensation of 2-aminopyridine with global trimer dehydrate in aqueous 
NaHSO3.8 
(vi) One-pot condensations of aldehydes, isonitriles,and 2-aminopyridines.9   
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  Moreover, methods ( i ) and ( vi ) are also used for the preparation of imidazo 
[1,2-a]pyrimidines.10,  
 
N
N
R
R1
N NH2
______R2
______R2N NH2
______R2
N NH2
N Cl
O
N
N
O
N
N
H
N
R1
R
R2
R1
X
O
COOR
COOR
N
N
N
H
O
O
O
O
OH
OH
OH
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The majority of imidazo[1,2-a]pyridine (IV) have been prepared by the 
reaction of a 2-aminopyridine (I) with a α -halo carbonyl compound (II) gives form  
(III). Which is further cyclize at room temperature and gives imidazo[1,2-a]pyridine. 
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PHARMACEUTICAL IMPORTANT 
  
Much research has been carried out with the aim to finding therapeutic value 
of aza-indolizine moiety since their discovery. A large number of substituted aza-
indolizine derivatives are prepared and tested for variety of biological activities. 
1. Gastric antisecretory12,13 
2. Local anesthetic14 
3. Antiviral15,16 
4. Hypnotic17 
5. Antianxiety18  
6. Antibacterials19,20 
7. Antifungal agents21 
8. Calcium channel blockers22 
9. Antiherputic activity23, 24 
10. Antiinflammatory,analgesic,antipyretic25, 26 
11. Antiulcer27 
12. Hypnoselective and anxioselective activities28 
13. α–Amyloid formation inhibitors29 
14. Active nonpeptide bradykinin β2 receptor antagonists30 
15. Nonsedative antioxytic31 
16. Benzodiazepine receptor agonists32 
17. Anticytomegalo-zoster and antivaricella-zoster virus33-35 
18. Cardiotonic agents36  
 
James J. Kaminski and co-workers37 had investigated the imidazo[1,2-a] 
pyridine derivatives 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy) imidazo[1,2-a] 
pyridine Type-II as an antiulcer activity. On the basis of the reported metabolism of 
zolimidine.They reported that the 3-cynomethyl and 8-phenylmethoxy groups have 
been established as metabolic sites in Type-II. 
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Type-II     (Zolimidine) 
 
Alain Gueiffier and co-worker38 are reported the synthesis and the       
antiviral activities of C-3 acyclic nucleoside analogues of imidazo[1,2-a]pyridine    
and pyrimidine. In contrast, some derivatives in the imidazo[1,2-a]pyrimidines    
series were devoid of antiviral activity.39 Some compounds showed a marked  
activity against cytomegalovirus and varicella-zoster virus. The most potent         
was Type-III (C), but this compound also showed marked cytotoxicity. Substantial 
antiviral activity again CMV was also noted for a,b,d,e,  while compounds a, b and c 
proved to be active against VZV replication and they also synthesized 3-
[[(hydroxyethyl)thio]methyl]-7-methyl imidazo[1,2-a]pyridine (Type-IV). Which shows 
antiviral activity against TK varicella-zoster virus.  
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N
N
CH3 S
OH 
  
Type-III                                Type-IV 
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Compd. R1            R2      R3  
a :-  H  7-Me-6,8-Br2  CH2C6H5 
b :-  H  8-Me   CH2CH3 
c :-  H  8-Me   CH2C6H5 
d :-  H  8-Me   CH2CH2OH 
e :-  H  5,7-Me2-6,8-Br2 CH2C6H5 
 
The imidazo[1,2-a]pyridine units appear as important building blocks in both 
natural and synthesis compounds.41-43 Such alterations in structure offer the 
potential to change the base pair recognition on DNA binding and to yield different 
pharmacokinetics profiles. Mohamed A.Ismail44 and co-workers synthesized some 
novel diamidino imidazo[1,2-a]pyridines like (Type-V) & (Type-VI) and 5,6,7,8-
tetrahydro imidazo[1,2-a]pyridines and their corresponding N-hydroxy and               
N-methoxy analogues which are potential prodrugs for this series and their 
evaluation versus Trypanosoma b.rhodesiense (T.b.rhodesiense) and 
Plasmodium falciparum (P.falcipaarum). Aromatic diamidines exhibit broad-
spectrum antimicrobial activity including effectiveness against the protozoan 
diseases caused by Trypanosoma sp and Plasmodium sp.45            
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N
R
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NH2
O
NH2
NH
 
            a-R : H,  b-R : Me  
 
Type-V 
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a- R :H; pera connection  
b- R :H; meta connection 
     
Type-VI 
 
James J. Kaminski and co-workers46 had been synthesized some             
novel compounds such as 3-(cyanomethyl)-2-methyl-8-(2-phenylethyl) imidazo            
[1,2-a]pyridine (Type-VII) and 2,3-dimethyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine 
(Type-VIII). Which shows Gastric-Antisecretory and Cytoprotective Properties. 
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Type-VII     Type-VIII 
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S. Kristjan, Gudmundsson and A. Brain Johns47 and A.Chaouni-Bendallah    
et al.48 worked on synthesis of a novel imidazo[1,2-a]pyridine shown in Type-IX with 
potent activity against herpes simpex viruses. 
 
 
N
N
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NH
N
N
NH
 
 
Type-IX 
 
Thus the important role displayed by imidazo[1,2-a]pyridine and it’s 
derivatives for various therapeutic and biological activities promoted us to 
synthesise some chalcone and acetylpyrazoline derivatives bearing imidazo[1,2-a] 
pyridine moiety in order to achive compounds having better activities. 
  
 
 
 
 
 
 
 
 
 
 
 
 
PART-I 
STUDIES ON CHALCONES 
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STUDIES ON IMIDAZOPYRIDINE DERIVATIVE
INTRODUCTION
O
A B
Type-I
The chemistry of chalcones have generated intensive scientific studies
throughout the world, specially interesting are their biological and industrial
applications. Chalcones are coloured compounds because of presence of the
chromophore and auxochromes.They are known as benzalacetophenones or
benzylidene acetophenones. Kostanecki and Tambor49 gave the name “Chalcone”.
Chalcones are characterized by their possession of a structure in which two
aromatic ring A and B are linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl styryl ketones, benzal
acetophenone-phenyl acrylphenone, γ-oxo-α-diphenyl-α-propylene and α-phenyl-β-
benzoethylene.
SHYNTHETIC ASPECT
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is the one that involves the Claisenschimdt
condensation of equimolar quantities of an arylmethyl ketone with arylaldehyde in
the presence of alcoholic alkali.50
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Several condensing agents used are alkali of different strength51,52 hydrogen
chloride53,54, phosphorous oxychloride55, piperidine56, anhydrous aluminium
chloride57, boron trifluoride58, aq.solution of borax59, amino acids60, and perchloric
acid61 etc.
MECHANISM
Chalcone formation proceeds through Aldol type condensation and the
process is catalysed by the presence of alkali.62Following are the steps of the
reaction mechanism.
Ph
O
H
+ OH
-
CH2
-Ph
O
HPh
O
+
Ph
O
Ph
O-
OH -
H+
Ph
O
Ph
OH
OH
-+ OH2-
Ph
O
Ph
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition.
REACTIVITY OF CHALCONES
The chalcones have been found to be a very good synthone to form
heterocyclic compounds are as under.
Chalcone…..24
(a) Chalcones with monoethanolamine in ethanol gives 1,4-oxazepines.63
(b) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-
thiazepines.64
(c) Chalcones on reaction with semicarbazide hydrochloride in ethanol
affords 1-carboxamide pyrazolines.65
(d) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords
pyridopyrimidines.66
(e) Oxiran67 can be prepared by the reaction of chalcone with H2O2 in basic
media.
(f) Cynopyridone68 derivatives can be prepared by the condensation of
chalcone with ethyl cynoacetate.
(g) Chalcone on reaction with barbituric acid gave barbitone69 derivatives.
(h) Chalcone give imine derivatives with amine in presence of sulfuric acid as
catalyst.70
(i) Pyrazolines71and its derivative can prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
(j) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines.72
(k) Isoxazoles73 can be prepared by the treatment of chalcones with
hydroxylamine hydrochloride and sodium acetate.
(l) Chalcones on condensation with malononitrile in pyridine forms 2-amino-
3-cyanopyrans.74
(m) Chalcones on treatment with urea in presence of alkali affords
2-oxopyrimidines.75
(n) Chalcones on treatment with thiourea in presence of alkali/acid yields
2-thienopyrimidines.76
(o) Chalcones on treatment with guanidine in presence of alkali affords
2-aminopyrimidines.77
(p) Chalcone reacts with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-1H-pyrimidines.79
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THERAPEUTIC INTEREST
Chalcones are potential biocides, some naturally occurring antibiotics and
amino chalcones probably own their biological activity to the presence of α, β -
unsaturated carbonyl group. Chalcone derivatives are associated with diverse
biological activity.
1. Antiallergic80
2. Carboxygenase inhibitir81
3. Antitumor82,83
4. Antimalatial84
5. Anticancer85
6. Antieishmanial86
7. Insecticidal87,88
8. Antiulcer89
9. Antiinflammatory90,91
10. Bactericidal92,93
11. fungicidal94,95
12. antiviral96
13. Anthelmintics97
Recently, Ni Liming et al.98 have synthesized chalcones and screened for
their antiinflammatory and cardiovascular activity. Kumar Srinivas et al.99 have
synthesised chalcones as an antitumor agent. Ko horng-Huey et al.100 have
prepared chalcones as an antiinflammatory agent. Nakahara Kazuhiko et al.101 have
synthesised chalcones as carcinogen inhibitors. Antitubercular agents of chalcone
derivatives have been prepared by Lin Yuh-Meei et al.102 Ezico et al.103 have
demonstrated that chalcone possess a valuable antiproliferation activity both on
sensitive cancereous cell and on cell which are resistant to common
chemotherapeutic drugs.Some of the chalcones have been patented for their use for
treatment of glueoma104 and showed antifungal105,106 aldose reductase inhibitores107,
anticancer108 and antimicrobial109,110 activities.
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Das B.P. et al.111 have found that chalcones possesses larvicidal properties.
Kim Min-Young et al.112 have synthesized chalcones and tested for their matrix
metalloproteinase inhibitor activity. Satyanarayana M. et al.113 have synthesised
chalcone derivatives as antihyperglycemic activity (Type-II)
CH2
R"
OH
O .
N
CH3
CH3
Type-II
Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by Modi et al.114 and Attia A.115, V. Mudalir et al.116
have prepared phenoxy chalcones and observed their insecticidal activity, Kammei
et al.117 have synthesised chalcone derivatives having antitumor activity.
De Vincenzo et al.118 and Han et al.119 have reported chalcone derivatives for their
antiinflammatory activity.
Aldose reductanse inhibitor activity of chalcone derivatives have been
reported by Okuyama et al.120 Chalcones are also associated with antitumor and
antifungal activity as reported by A. Tsotitns and co-worker.121 Antifeedant activity of
chalcones have been observed by Sarma and Sreenivasulu.122 Liu Mei et al.123 have
prepared antimalarial chalcones. Opletalova Veronika et al.124 have synthesised
chalcones and screened as cardiovascular agents. Moreover, it has been found that
chalcone derivatives possesses nitric oxide inhibitor125,126 anti HIV127,128 and
antiproliferative129,130 activities.
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Meng C.Q.et al.131 discovered of novel heteroaryl substituted chalcones as
inhibitors of TNF-alpha-induced VCAM-1 expression (Type-III).
O
MeO
MeO
OMe
OMe
OMe
S
Type-III
Moreover, Khatib S.et al.132 synthesized some novel chalcones as potent
inhibitors (IV). Ko H.H. et al.133 have prepared some new chalcones as potent
inhibition of platelet aggregation. Ziegler HL, et al.134 reported some new chalcones
as antiparasitic. Go ML,et al.135 have described the synthesis and biological
activities of chalcones as Antiplasmodial. Xue CX et al.136 synthesized as
antimalarial agents. Fu Y et al.137 have synthesized Licochalcone-A Type-IV.
OH
OH O
OH
OH
Type-IV
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Furthermore, Alcaraz M.J, et al.138 have described the role of nuclear factor-
kappa β and heme oxygenase-1 in the mechanism of action of anti-inflammatory
chalcone derivative in RAW 264.7 cells. Nerya O et al.139 have prepared some new
Chalcones as potent tryosinase inhibitors.
O
OCH3
OH
OCH3
O
Type-V
Sabzevari O. et al.140 have constructed some new chalcone derivatives as
Molecular cytotoxic mechanism of anticancer hydroxy chalcones (Type-V).
Recently, Ban H.S. et al.141 synthesized some novel chalcones as inhibition
of lipopolysaccharide-induced expression of inducible nitric oxide synthesis and
tumor necrosis factor-alpha by 2’-hydroxychalcone derivatives in RAW 264.7 cells.
Hollosy F.et al.142 have prepared some new chalcones as Plant-derived protein
tyrosine kinase inhibitors as anticancer agents.
Chalcone beaing a very good synthon variety of novel heterocycles with good
pharmacological profile can be designed. These valid observation led us to explore
chalcone chemistry by synthesising several derivatives like pyrazolines,
cyanopyridines, cyanopyridones, cyclohexenones, indazoles and aminopyrimidines
bearing different heterocyclic ring systems for medicinal value, in order to achieving
better therapeutic agents, this study described as under.
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SYNTHESIS AND THERAPEUTIC EVALUTION OF (2Z)-3-[2-(4-CHLOROPHENYL)
-8-METHYL IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-ARYL PROP-2-EN-1-ONE.
Chalcone derivatives have been found to be associated with various
pharmacological activities. These finding encouraged as to synthesize, some new
novel synthesis. (2Z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one derivatives Type-I synthesized by the condensation of
2-(4-chlorophenyl)-6-methyl imidazo[1,2-a]pyridine-3-carbaldehyde with various
substituted ketone in methanol.
N
N
CH3
Cl
O
R R= Aryl
Type-I
The constitution of the synthesized products have been characterized
by using elemental analyses, infrared and 1H-nucleur magnetic resonance
spectroscopy and further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity toward Aspergillus niger at a concentration of 40μg/ml.The 
biological activities of the synthesized compound were compared with standard
drugs. The detail have been cited in Part-I Experimental - (E).
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REACTION SCHEME
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IR SPECTRAL STUDIES OF (2Z)-3-[2-(4-CHLOROPHENYL)-8-METHYL
IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2918 2975-2950 143-a
-CH3 C-H str.(sym.) 2852 2880-2860 ”
C-H i.p.def 1475 1470-1435 ”
C-H o.o.p.def. 1361 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1517 1520-1480 ”
C-H i.p.def 1014 1070-1000 ”
C-H o.o.p.def. 819 835-810 ”
Moiety C=N str. 1587 1610-1590 143-c
C-N str. 1176 1230-1020 ”
C-Cl str. 795 800-750 ”
Chalcone C=O str. 1658 1700-1640 143-d
CH=CH- str. 1640 1644-1618 ”
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NMR SPECTRAL STUDIES OF (2Z)-3-[2-(4-CHLOROPHENYL)-8-METHYL
IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE.
Internal Standard ; TMS ; Solvent :CDCl3 ; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.70 3H singlet Ar-CH3
2 3.90 3H singlet Ar-OCH3
3 7.55 2H doublet Ar-H(b,b')
4 7.00 1H triplet Ar-Hd
5 6.97 2H doublet Ar-H(a,a')
6 7.55 1H doublet Ar-Hi
7 7.95 2H doublet Ar-H(f,f')
8 8.15 1H doublet Ar-Hh
9 7.75 2H doublet Ar-H(g,g')
10 7.27 1H doublet Ar-Hc
11 8.43 1H doublet Ar-He
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MASS SPECTRAL STUDIES OF (2Z)-3-[2-(4-CHLOROPHENYL)-8-METHYL
IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE.
Chalcone…..36
ANTIMICROBIAL ACTIVITY
Products : Chalcones
Method : Cup-plate
Gram positive bacteria : Staphylococcus aureus
Bacillus coccus
Gram negative bacteria : Pseudomonas
E. coli
Fungi : Aspergillus niger
Concentration  : 40μg 
Solvent : Dimethyl formamide
Standard drug : Ampicillin, Amoxicillin, Ciprofloxacin,
Norfloxacin, Greseofulvin.
The antimicrobial activity was compare with standard drug viz ciprofloxacin,
Amoxicillin, Benzyl-penicillin and antifungal activity was compared with viz
greseofulvin. The zone of inhibition were measured in mm.
All the compounds have been evaluated for antimicrobial activity using Cup-
plate agar diffusion method at a concentration of 40μg using DMF as a solvent 
against different strains of bacteria and fungi as describe in experimental (E).
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EXPERIMENTAL
Synthesis of (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
(4-methoxyphenyl)prop-2-en-1-one.
[A] Preparation of 2-chloro-1-(p-chlorophenyl)ethanone.
A mixture of chlorobenzene (1.13gm,0.01m) and di-chloromethane is
maintain at 0 °C, then add anhydrous AlCl3 (1.8gm,0.01m) and Chloracetyl Chloride
(1.13gm, 0.01m) Stirred reaction mixture at 20 °C for about 10 hrs. Finally pour the
reaction mixture on crushed ice then add cons. HCl and solid product was isolated
with help of di-chloromethane and wash with petrolium ether. Yield 85% (1.60gm) ;
m.p.95 °C ; (C8H6Cl2O ; Found : C,50.90%;H,3.25%; Required : C,50.83%;H,3.20%)
TLC solvent system : Ethyl acetate : Hexane ( 3:7)
[B] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
A mixture of 2-chloro-1-(p-chlorophenyl)ethanone (1.89gm,0.01m) and
2-amino-3-methyl pyridine (1.08gm,0.01m) in DMF was refluxed at 140 °C for about
6 hrs. Finally pour the reaction mixture on crushed ice then solid product was
isolated and purified by methanol. Yield 83% (2.0gm) ; m.p.150 °C ; (C14H11N2Cl ;
Found : C,69.39%;H,4.65%;N,11.62% ; Required : C,69.28%;H,4.57%;N,11.54%)
TLC solvent system : Ethyl acetate : Hexane ( 2:8)
[C] Preparation of 2-(p-chlorophenyl)- 8- methyl imidazo[1,2-a]pyridine- 3-
carbaldehyde.
A compound 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine (2.43gm,
0.01m) was added in a mixture et Vilsmeire-Haack reagent (prepared by dropwise
addition of 3.27ml POCl3 in ice cooled 27ml DMF) and refluxed for 6 hrs.
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The reaction mixture was poured on to crushed ice followed by neutralization
using sodium bicarbonate. Crude product was isolated and crystallized from DMF.
Yield 80% (2.34gm) ; m.p.179 °C ; (C15H11N2OCl ; Found : C,66.63%;H,4.18%;
N,10.43 ; Required : C,66.55%;H,4.10%;N,10.35%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
[D] Preparation of (2Z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-(4-methoxyphenyl)prop-2-en-1-one.
A mixture 2-(4-chlorophenyl)-8-methylimidazo[1,2-a]pyridine-3-carbaldehyde
(2.70gm,0.01m) and 1-(4-methoxyphenyl)ethanone (1.50gm,0.01m) was refluxed in
methanol for 6 hrs. NaOH is used as catalyst. The contents were poured on to
crushed ice and product isolated was crystallized from di-chloromethane. Yield 75%
(3.01gm) ; m.p. 189 °C ; (C24H19N2O2Cl; Found : C,71.29%;H,4.52%;N,6.69% ;
Required : C,71.55%;H,4.75%;N,6.95%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Chalcone derivatives have been obtained. The physical data
are recorded in Table No.- 1(B).
[E] Antimicrobial activity of (2Z)-3-[2-(4-chlorophenyl)-8-methyl imidazo
[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one.
All the products have been evaluated for antimicrobial activity as described
as under.
(a) Antimicrobial activity
It was carried out by cup- plate diffusion method which has been described
as under.
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(I) Antibacterial activity
The purified products were screened for their antimicrobial activity. The
nutrient agar broth prepared by the usual method, was inoculated aseptically with
0.5 ml of 24 hrs. old subcultures of B.cocus, S.aureus, Pseudomonas and E.coli
in separate conical flask at 40-50 °C and mixed well by gentle sacking. About 25ml
content of the flask were poured and evenly spreaded in a petridish (13mm in
diameter) and allowed to set for 2 hrs. The cups (10mm in diameter) were formed by
the help of borar in agar medium and filled with 0.04ml (40mg) solution of sample in
DMF.
The plates were incubated at 37 °C for 24.0 hrs. and the control was also
maintained with 0.04 mole of DMF in a similar manner and the zones of inhibition of
bacterial growth were measured in millimeter.
(II) Antifungal activity
A.Niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on Subouraud’s agar slants. Steriled Subouraud’s agar
medium was inoculated with 72 hrs. Old 0.5ml suspension of fungal spores in a
separate flask.
About 25ml of inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The cups (10 mm in diameters) were punched in petridish
and loaded with (0.04gm) of solution of sample in DMF. The plates were incubated
at 30 °C for 48 hrs. After the completion of incubation period, the zone of inhibition
of growth in the form of diameter in mm was measured. Along the test solution in
each petridish one cup was filled with solvent which act as control. The zones of
inhibition are recorded in Table No.- 1(A).
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TABLE NO.- 1A BIOLOGICAL SCREENING OF (2Z)-3-[2-(4-CHLOROPHENYL)
-8-METHYL IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-ARYL PROP-2-EN-1-ONE.
Sr.
No.
R
Zone of Inhibition in m.m.
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
1a C6H5- 17 16 13 12 19
1b 4-CH3-C6H4- 15 13 15 14 13
1c 4-OCH3-C6H4- 16 15 14 15 12
1d 4-Cl-C6H4- 18 18 15 16 14
1e 4-F-C6H4- 16 14 15 15 16
1f 4-Br-C6H4- 14 12 13 12 13
1g 4-NH2-C6H4- 15 14 14 13 15
1h 4-NO2-C6H4- 13 12 13 14 15
1i 4-OH-C6H4- 19 16 18 18 18
Stdn Ampicillin 20 19 21 22 -
" Amoxicillin 22 20 20 21 -
" Ciprofloxacin 24 23 22 20 -
" Norfloxacin 23 21 21 22 -
" Greseofulvin - - - - 24
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TABLE NO.- 1B PHYSICAL CONSTANTS OF (2Z)-3-[2-(4-CHLOROPHENYL)
-8-METHYL IMIDAZO[1,2-a]PYRIDINE-3-YL]-1-ARYL PROP-2-EN-1-ONE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
1a
1b
1c
1d
1e
1f
1g
1h
1i
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C23H17ClN2O
C24H19ClN2O
C24H19ClN2O2
C23H16Cl2N2O
C23H16ClFN2O
C23H16ClBrN2O
C23H18ClN3O
C23H16ClN3O3
C23H17ClN2O2
372.5
386.5
402.5
407.0
390.5
451.5
387.5
417.5
388.5
215.0
262.0
189.0
185.0
140.0
243.0
165.0
161.0
149.0
0.54
0.58
0.60
0.59
0.44
0.62
0.56
0.56
0.49
59.0
56.0
75.0
72.0
65.0
57.0
55.0
70.0
54.0
7.51
7.24
6.95
6.88
7.17
6.20
10.83
10.06
7.20
7.36
7.12
6.78
6.76
6.98
6.15
10.79
9.88
7.04
Solvent System : Ethyl acetate : Hexane (5:5)
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INTRODUCTION
Pyrimidine (1) is a six membered heterocyclic compound consisting of
two nitrogen atoms at 1 and 3 positions of heterocyclic ring.
N
N
Pyrimidine
(1)
Generally Pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine and 2-amino-substituted-pyrimidine are studied.
Pyrimidines have been isolated from the nucleic acid hydrolysates. Pyrimidines have
been used as compounds that interfere with the synthesis and functioning of nucleic
acids e.g. fluorouracil, which has been used in cancer treatment. Also there are
some thiouracil derivatives, which produce adverse reduction in susceptible patients
and found more potent and less likely to produce side effects and is being widely
used.143 There are several other important groups of pyrimidines with medicinal
uses.
Pyrimidine ring carrying various substituents may be built up from two or
three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another heterocycles
such as hydration of purine, but such methods are rarely used. Pyrimidine is best
considered as a resonance hybrid to which the uncharged equivalent
Kekule structures 2 and 2a and charged structures 2b and 2g contributes.
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The self consistent (pi) electron densities required for the ground state of
pyrimidines are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respectively144.
Despite considerable localization of (pi) electrons at nitrogen atoms of pyrimidines
the ring system is still sufficiently aromatic to possess substantial stability. This has
a great advantage in the primary synthesis of pyrimidines.
N
N
N
N
N
N
H
NH
N
++
(2) (2a) (2b) (2c)
N
N.
+
N.
N
N
N.
N.
N+ +
+
(2d) (2e) (2f) (2g)
The first primary synthesis from aliphatic fragments was carried out by
Frankland et al. in 1848. Since then a many distinct primary synthetic methods have
been devised.145-154 It is also possible to prepare pyrimidines from other heterocyclic
compounds such as pyrrole155, imidazole156, isoxazole and oxazole 157-158,
pyridine159, pyrazine160, 1,3,5-triazine161, oxazine162, thiazine163 by different
processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of
pyrimidine.164
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(b) By the condensation of malonic ester and urea led to formation of
pyrimidine.165
(c) By the condensation of formamidine with phenylazomalononitrile led to
formation of 4,5,6 – triaminopyrimidine.166
(d) By the condensation of aromatic aldehydes, ß-ketoester or substituted ß-
ketoester with urea or thiourea led to formation of pyrimidines.167
(e) By the condensation of thiourea and substituted ß-ketoester in presence of
sodium ethoxid e led to formation of 2-mercaptopyrimidines.168
(f) By the condensation of chalcones with dicyandiamide in presence of
piperidine led to formation of pyrimidines.169
(g) By thermal or microwave irridiation of thiourea and substituted ß -ketoester
in presence of dimethylformamide led to formation of substituted
tetrahydropyrimidines.170
(h) One pot synthesis of substituted dihydropyrimidin-2-ones catalysed by
CuCl2.171
(i) Synthesis of 3,4-dihydropyrimidin- 2- (1H)- ones/thiones under micro wave
irradiation.172
(j) One pot efficient and novel synthesis of dihydropyrimidin-2-(1H)-ones
catalysed by Tin (II) chloride (SnCl2).173
(k) By microwave induced eco-friendly solvent free Biginelli reaction catalysed by
calcium chloride.174
Pyrimidines have found their applications as herbicidal175 and pesticidal176-
177 agents. Yoshida et al.178 have synthesized 4-amino-5-formyl-2-mercapto
pyrimidines as agrochemical intermediates. C. Srivastava et al.179 have
synthesized new substituted pyrimidines (3) as potential insecticides. N. Yasushi et
al.180 synthesized 6-(1-fluoroethyl)-5-iodo-4-alkylamino Pyrimidines(4) as
pesticides for agriculture and horticulture. Besides such a great biological
importance of pyrimidines they also contribute to an important
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class of dye viz. trichloro pyrimidine181 dye which is a reactive dye. Pyrimidines
also have applications in liquid crystal composition.182 Many synthetic members of
pyrimidines are important as vulcanizing accelerator agents and photography
stabilizer.183
N
N
NHR
I
FHCH3C
(3)
N
N
S O
O
CH2CH2COOC2H5
CH2CH2COOC2H5
R
R
(4)
R=Alkyl/Aryl
PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobials
and antitumor agents. Uracil, thymine, alloxan, vicine and divicine, cytosine,
chroticacid, willardiline, tetradotoxine, becimethrian (5),blasticidine (6) ,
cougerotin , amicetin , bamicetin and plicacetin, phleomicine, blemycin and
related families (7).
N
N
NH2
OCH3
OH
NN O
O
COOH
NH
O NH2
CH3
NH2
NH N
N
NH2
CH3
NH
R2
O
R1
(5) (6) (7)
Pyrimidine…..46
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring system is
also present in Vitamin B2 and folic acid. Pyrimidine ring system having a
mercapto group occupy a unique position in medicinal chemistry.184 These types
of derivatives play a vital role in biological processes185-187 as well as synthetic
drugs.188
Some of the therapeutic activities of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid 189-190 (b) Antitumor191-193
(c) Antihypertensive194-196 (d) Antiinflammatory197-199
(e) Diuretic200 (f) Antimalarial201-203
(g) Antispasmodic 204 (h) Anticonvulsant205
(i) Antineoplastic 206,207 (j) Anthelmintic208
(k) Antimicrobial209-234 (l) Cardiovascular235-237
(m) Antiviral238-241 (n) Platelet aggregation inhibitor242,243
(o) Antihistamine244,245 (p) Anti-HIV246,247
(q) Antitubercular248
The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids has been
a subject of interest for some time, the intense focus on the medicinal chemistry
of oligonucleotides dates perhaps to not more than five years. As a result of
this, the scope of medicinal chemistry has recently been expanded enormously,
but the biological data of supporting the conclusions about synthetic strategies
have just begun to emerge.
Modifications in the base, sugar and phosphate moieties of
oligonucleotides and oligonucleotide conjugates have been reported. The
subjects of medicinal chemical programmes include approaches to create
enhanced affinity and more selective affinity for RNA or duplex structures, the
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ability to cleave nucleic acid targets, enhanced nuclease stability, cellular
uptake and distribution, in vivo tissue distribution, metabolism and clearance.
Although substantial progress in the medicinal chemistry of oligonucleotides has
been made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifications
and activity in vitro suggest that the next generation of oligonucleotides may
display substantially improved potencies and selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines have been synthesized
and now incorporated into oligonucleotides and evaluated. The principle sites
of modification are C-2, C-4, C-5 and C-6 (8). These and other nucleoside
analogues have recently been thoroughly reviewed.250
N
N
1
2
3 5
6
4
C-4
C-5
C-6C-2
Sites of Pyrimidine Modification (8)
In as much as the C-2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C-2 alkyl modified pyrimidines have shown
unattractive hybridization characters. However, an oligonucleotide containing
2-thiopyrimidine(9) was found to hybridize well to DNA and, in fact even better
to RNA with a thermal melting temperature (Tm) value of 1.5 ° C/modification.
In a different study, oligoribonucleotides with 2’-o-methyl-2-thiouridine (10)
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exhibited a thermal melting temperature (Tm) value of +5.5 °C/modification
when hybridized against RNA resulting from a highlly preoganized RNA-like C-3’
endo conformation (attributed to the combination of 2-thio modification and 2’-o-
Mesubstituent). Oligonucleotides with this modification also exhibit better
hybridization discrimination for the wobble uracil-guanosine (U-G) base pair
formation compared to the (8) Sites of Pyrimidine Modification normal uracil-
adenine (U-A) base pair. This selectivity is a result of weaker hydrogen bonding
and increased steric bulk of the 2-thiocarbonyl group.251
NH
N
O
S
O
O CH3
(9) (10)
NH
N
O
CH3
S
O
o
o
o
o
In contrast, the Pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines (11,12) have been
incorporated into oligonucleotides with no significant negative effect on
hybridization. However, recent studies have shown destabilization in the normal
uraciladenin (U-A) base pair formation and stabilization of the wobble uracil
guanosine (U-G) base pair for 4-thiouridine. A bicyclic 4-methoxy analog of
cytosine were shown to hybridize with both purine bases in DNA with thermal
melting temperature (Tm) values approximately equal to that of natural base
pairs. Additionally, a fluorescent base has been incorporated into
oligonucleotides and shown to enhance DNA-DNA duplex stability.252
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The Pyrimidine modification at C-5 position including halogenated
nucleosides have been reported. Although the stability of duplexes may be
enhanced by incorporation 5-halogenated uracil containing nucleosides, the
occasional mispairing with guanidine and the potential that the oligonucleotide
might degrade and release toxic nucleosides analogs cause concern. Oligo-
nucleotides containing 5-propynylpyrimidine (14,15) modification have been
shown to enhance the duplex stability thermal melting temperature
(Tm = 1.6 °C/modification),and support RNase H activity. The 5-heteroaryl-
pyrimidines were also shown to increase the stability of duplexes. A more
dramatic influence was reported for the tricyclic 2’-deoxycytidine
analoges, termed phenoxazine, exhibiting an enhancement of
2-5 °C/modification, depending on the positioning of the modified bases.253
N
N
NH2
O
O
CH3
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o
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As expected, modifications in the C-6 position of pyrimidines are highly
destabilizing. Oligonucleotides containing 6-azapyrimidines (16) have been
shown not only to reduce the thermal melting temperature (Tm) value by 1-2 °C
per modification, but also to enhance the nuclease stability of oligonucleotides
and to support E. coli RNase H-induced deradation of RNA targets.254
(16)
N
N O
O
NH
O
O
N
+
H
H
H
o
o
PYRIMIDINE MODIFICATIONS (Non-nucleotide)
The increasing interest in the early 1970s in properties and use of
interferon (IFN) together with the difficulty in producing useful amounts of
interferon (IFN) led to the search for agents that would induce IFN in the host.
Precedenced at that time for interferon (IFN) inducers included viruses and
bacterial wall constituents and entities of large molecular weight such as the
polynucleotides. There were also several examples of low molecular weight
substances such as certain antibiotics and the antiviral agent, tilorone.255 In
1976 it was reported that 6-methyl pyrimidinone (2-amino-5-bromo-6-methyl-
4-(3H) pyrimidinone, ABMP) induced circulating levels of interferon (IFN) in
several animal specis upon oral or intraperitoneal administration.256 Subsequent
structure-activity studies yielded a more potent and less toxic 6-phenyl ananlog
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called ABPP or bropirimine(2-amino-5-bromo-6-phenyl-4-(3H)-pyrimidinone)
(figure 1 and Table 1).257,258 Bropirimine and related 6-aryl analogs were
examined extensively for efficacy in virus and tumor models, along with their
immunomodulatory properties and overall pharmacological effects.259
N
N
4
2
3
1
5
6
OH,NH2,NR2,N3Cl,H,NHCH2,
CH2OH,OCH2CH2NH2
F,Cl,Br,I,Et,MeCH=CH2,Prn,CHCCH2,
CO2Et,MeCH2OCH2CH2,NO2,H,Ph,
CH2Ph,CH2SiMe3
Alkyl, Aryl,
Heteroaryl
N-OH
Me, Et, Pr
NH2,RCONH2 ,Me2N,
O2NNH, Me2 NCH=N,
CHONH,OH,H2
NC(=NH)NH
W here, Pre lim inary SAR of antiviral activity o f
pyrim id inones (underlined substituents were active)
Table - I
Antiviral Activity
Monosubstituted Disubstituted Heterocyclic
Active 2-F,OMe, Me 3,5-OMe 1Naphthyl
3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, Butyl, 2,3-OMe 2-Napthyl
OH,OCH2Ph, OMe 1-Furyl
4-Pyridyl
2Quinoline
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As with the polynucleotides, the pyrimidinones exhibited significant
activity against interferon (IFN) sensitive viruses such as Semliki Forest virus in
vivo. How ever, in addition, they exhibited prophylactic and therapeutic activity
upon either local or systemic administration to rodents infected with a variety of
DNA viruses, such as the herpes viruses (HSV-1, HSV-2, CMV and
pseudorabies), and when administered intranasally for upper respiratory
infections, such as infectious bovine rhinortacheites, influenza A and para-
influenza-3.Particularly interestion activity was noted with bropirimine on
intravaginal administration in protection against HSV-2 intravaginal infection in
guinea pigs, an important model for genital herpes in humans.260 Bropirimine
also exhibited activity when given either intraperitoneally or orally to mice
infected with Listera monocytogenes. The efficacy in this model was not
abrogated by the addition of anti-interferon (IFN) antibody.261
Pyrimidines as Antifolates
During a preliminary clinical trial designed to establish safety and
suitability for use in the treatment of cancer, Farber found the folic acid
derivatives pteroyldiglutamic acid (17) and pteroyltriglutamic acid (18) were
accelerating the growth of malignant cells in the bone marrow of patients with
acute leukaemia. He obtained the newly synthesized antifolate pteroylaspartic
acid from Subba Row, from which encouraging results were obtained in children
with acute leukaemia. Better responses were observed with the aminopterin
(19) and methotrexate (20). Injections of methotrexate induced temporary
remissions in 30% of children, but Farber and his colleagues later combined it
with drugs such as cortisone and mercaptopurine to achieve results which
paved the way towards the currentposition where most children can be cured
of the disease if given the appropriate treatment. The precise model of action
of the antifolates became apparent in 1952. This was the inhibition
of dihydrofolate reductase, the enzymes that catalysed the transformation of folic
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acid so that it could be utilized for the synthesis of thymine for incorporation into
DNA. Surprisingly, no other antifolate has emerged to rival methotrexate in the
treatment of either acute leukaemia or cancers.
n
CONH
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N
N
NH CONHCH
NH2
O COOH
CH2CH2
COR
CH2CH2COOH
(17) n = 0, R = NHCH(COOH)CH2CH2COOH (18) n =2, R = OH
n
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N
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N
N
NH CONHCH
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O COOH
CH2CH2
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CH2CH2COOH
(19) R = H (20) R = Me
Of the various halogenated pyrimidines which have been prepared, only
the fluorinated pyrimidines and nucleosides have useful antitumour activity,
and of these the most significant are 5-fluorouracil (FU) and it’s 2’-
deoxyribonucleside (FUdR; Floxuridine). Both of these drugs have found wide
uses in patients suffering from metastatic cancer, and have been administered
both singly and in combination therapy. The presence of flourine, which cannot
be abstracted by base, halts the process. In contrast, the 5’-monophosphate of
5-chloro-, 5-bromo- and 5- iodo- 2’-deoxyuridine, in which the halogen atom
is bulkier and less electro- negative, have little or no useful inhibitory activity for
the enzyme. The drugs of
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fluorouracil (FU) showing good antitumour activity includes it’s
1-t-butyl carbamoyl262, 1-hexylcarbamoyl263 and 1-methoxycarbonylmethyl
carbamoyl264 derivatives, 5’- deoxy-5-fluorouridine265 and methyl-1-(5-fluoro-
1-H-2-oxopyrimidin- 4- yl)-BD- glucopyranuronate (21).266 All of these contain
in essence the fluorouracil (FU) moiety, ready via oxidative or hydrolytic means.
5-Fluoropyrimidin-4(1H)-one, with activity against tumours in experimental
animals, is a different type of prodrug, being oxidized to 5-fluorouracil (FU) by
xanthine oxidase.267
A number of prodrugs of FUdR have also been prepared a notably potent
member being 5-bromo-6-methoxydihydro-5-fluro-2’-deoxyuridine (22).268
Finally, a different species of fluoropyrimidine derivative, which as its 5’ mono
phosphate inhibits thymixylate synthetase is 5-trifluoromethyl-2’-
deoxyuridine( Trifluridine); (23) it possesses a higher therapeutic index against
adenocar-cinoma 755 in mice than 2’-deoxyribo-nucleoside (FUdR;
Floxuridine).269
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As part of a continuing effort of develop novel classical antifolates as
dihydrofolates (DHFR) inhibitors and as antitumor agents, A. Gangjee et al.270
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have reported the 5-substitutedfuro [2,3-d] pyrimidines (24) for enzyme
inhibitoryactivity and antitumor activity.
N
N
O
(CH2)n
NH2
NH2
CO-L-Glu
(24) n = 4
PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activity,
in which the base is conjugated to a modified suger ring have been reported.
Although D-Arabinofuranosyl uridine (ara-uridine) shows no useful acitivity and
5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth of
sarcoma 180 and L1210 cells in culture.271 Other thymidine analogues with
similar activity include 5-azidomethyl-,5-aminomethyl and 5-hydroxymethyl-
2’-deoxyuridine272. 3’-Amino-3’-deoxy thymidine273 and 3’-amino-2’,3’-
dideoxycytidine274 also posses strong activity against L1210 leukaemia 2’-
Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU);(25) is highly
active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815 cell
lines both in vitro and in vivo.275 2-B-D-Ribofuranosylthiazole-4-carbox
amide (Tiazofurin; 26) has aroused much interest recently for its activity against
solid tumour such as lung carcinoma. It is metabolized to an analogue of NAD
in which the thiazole-4-carboxamide moiety replaces the nicotinamide ring.
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However, it also depresses the synthesis of DNA and RNA, and thus merits
inclusion as an antagonist of normal purine and pyrimidine metabolism.276
(26)
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OH OH
S N
CONH2
Targets for Antiviral Chemotherapy
Viral chemotherapy presents a quite different problem from tumor
chemotherapy. A virus277 consists of a core of nuclear material, DNA or RNA,
containing specific viral genes, which may be associated with ‘core proteins’, and
which is surrounded by a protective proteincoat. The coat may have functional
protein appendages, and there may be present an ‘envelope’, rich in lipoprotein
and glycoprotein. The virus possesses no energy-producing or protein
synthesizing machinery of its own. In order to reproduce, it must therefore
become adsorbed to a host cell, be transported across the cell membrane, and
uncoat in order that its viral genes may be expressed. The genome may require
to be transported to the cytoplasm or the nucleus. The nuclear material must
then be replicated, and the viral genes also transcribed into RNA (assuming that
we are dealing with a DNA virus) and translated into virally specified protein. In
addition to the coat protein, viral enzymes will be produced in this process, and
these are vital for suborning the host cell’s internal biochemistry to serve
the requirements of the virus. Before the viral proteins can be made, a process of
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maturation of the viral mRNA molecules, involving guanylylation and methylation
to produce a ‘cap’ structure containing 7-methylguanosine 5’-phosphate in a
5’- 5’-pyrophosphate structure at the 5’- end of the mRNA, must occur. Once
the synthesis of the components needed to make fresh viral particles has been
completed, maturatian occurs, in which the nucleic acid and protein components
are assmbled to from the complete viral particle or virion, and finally this is
released from the cell as a new , infective virus. RNA viruses require that their
nucleic acid be replicated also, in order that new viral particles can form. Some
RNA viruses code for an enzyme ‘transcriptase’ or ‘replicase’ (RNA-directed
RNA polymerase), which replicates RNA strands directly without involving
DNA278 while others encode an enzyme ‘reverse transcriptase’ (RNA-directed
DNA polymerase), which transcribes the RNA sequence into DNA-the reverse of
the usual sequence which can subsequently become integrated into the host cell
chromosome and is transcribed to from copies of the viral RNA.279 Purine and
pyrimidine antimetabolites which are active against viruses are thus most likely
to be effective by inhibiting specifically the viral enzymes which are required to
replicate the viral nucleic acids, or inhibiting the viral enzymes responsible for
transcription and capping of mRNA, without inhibiting the corresponding
enzymes of the host cell.
Alternatively, incorporation of an antimetabolite into a viral nucleic acid
causing the cessation of strand synthesis, or otherwise disturbing the normal
function of the nucleic acid in replication or in directing protein synthesis, offers
another way of preventing the replication of functional virus.280 Again, it is
important that the integrity of the nuclear material of the host cell should not be
compromised.One therefore seeks to exploit the differences between the viral
enzymes to the discomfiture of the virus. 5’-Amino- 5- iodo- 2’,5’-
dideoxyuridine(Aminoidoxuridine;28) displays good antiherpes activity and is
less cytotoxic than (27).281,282 The Phosphorylation of Aminoidoxuridine
(28) is catalyzed specifically by virus-induced thymidine kinase, and thus
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Aminoidoxuridine(28) is only potentiated in virus-infected cells. It inhibits the
synthesis of DNA in infected cells. The 5-bromo-, 5-chloro- and 5-
trifluoromethyl derivatives of 5’-amino-2’,5’-dideoxyuridine also exhibit
antiviral activity.283 5-Iodo-2’-deoxcytidine (29) and 5-bromo-2’-
deoxycytidine (30) also show useful activity against herpes viruses and
vaccinia with less cytotoxicity than the uridine compounds and more selective
inhibition of virus replication. C. K.Chu284 et al. have prepared pyrimidine
nucleosides (31) and reported in vitro antiviral activity against varicella zoster
virus (VZV).
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(27, 28) R = OH, NH2 (29,30) X = I, Br (31) X = Cl, Br, I
PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for viral
DNA polymerases is the most well-studied and successful approach to viral
chemotherapy, and has led to the discovery of several clinically useful antiviral
drugs.This strategy, however, has inherent limitations. Human DNA polymerases
also required dNTP’s and the chemical mechanisms of polymerization by the
viral and human enzymes are similar. Nucleoside analogs often have significant
host toxicity that is probably related to inhibition of host cell DNA synthesis.
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Nevertheless, these compounds constitute the major class of antiviral drugs,and
this approach is likely to yield additional active compounds in the near future. For
the long term, however, other strategies may ultimately lead tumor selective
agent within lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host
enzyme than the viral enzyme, which requires that there be structural differences
between the enzyme active sites. For reverse transcriptase, the most well
studied inhibitor is 3’-azido-3’-deoxythymidine (AZT; 32), which is currently
used clinically to treat AIDS.285,286
N
NH
O
OH
N3
O
O
CH3
(32)
3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase with
an IC50 of 40nM287, but is 100-300 times less active against mammalian DNA
polymerase and DNA polymerase . The reason for this selectivity is not clear
since 3’-azido-3’-deoxythymidine (AZT) is a chain terminator for mammalian
DNA polymerases and inhibits normal cellular DNA synthesis.288 Several other
dideoxy nucleoside analogs have been shown to be potent inhibitors of HIV
replication in vitro.289,290 In general, these compounds have the same
mechanism of action as 3’-azido- 3’-deoxythymidine (AZT), that is, intracellular
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conversion to the triphosphate derivative and subsequent inhibition of HIV
reverse transcriptase. Some of these compounds are simply analogs of the
natural 2’-deoxy- nucleoside in which the 3’-OH group has been replaced with
a hydrogen, such as 2’,3’-dideoxycytidine(33), 2’,3’-dideoxyadenosine(34)
and 2’,3’-dideoxy thymidine(35). Other analogs contain a 2’-3’ double bond,
such as 2’3’- dide-hydro-2’,3’-dideoxythymidine (36). Several related analogs
with other modifications to the ribose ring or the heterocyclic base moiety have
also been reported to have activity against HIV or HIV reverse
transcriptase.291,292
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Recently, P. Khalili et al.293 have carried out biochemical and
pharmacokinetic evaluation of a novel nitric oxide donor pyrimidine nucleoside
hybrid drug as a potential anticancer / antiviral agent. Rostom et al.294
have synthesized and screened certain 2-(benzoxazol-2-yl-amino)-3H-4-
oxopyrimidines for in vitro anti-HIV activity. R. A. Nugent et al.295 have
synthesized pyrimidine thio ethers (37) and evaluated for inhibitory properties
against wild-type HIV-1 reverse transcriptase. F. Manetti et al.296 have
synthesized novel pyrimidines (38) with nanomolar activity toward recombinant
HIV-1 and mutant HIV-1 strains.
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R1= 2,6-(Cl)2, 4-F R=Ph,Me,CO2Me,CONMe2,CONEt2
R2=4-OCH3,4-NO2, 4-CN, 4-Br
(37) (38)
A family of tri substituted pyrimidines has been described as selective
COX- 2 inhibitors. To explore the usefulness of pyrimidine derivatives as
potential NSAIDs. Aurelio Orjales et al.297 have synthesized novel pyrimidine
derivatives(39) and (40). In vitro biological evaluation of these compounds has
provided information to determine the structural features necessary for COX-2
inhibitory activity.
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X
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S
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CH3CH3
(39) Y = CH; X, Z = N (40) Y, Z = N; X = CH
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In view of procuring highly potent biodynamic agents and after reviewing
recent literature survey on oxo/thio/amino pyrimidines for their various
methods of synthesis and different pharmacological activities, synthesis of
pyrimidines have been undertaken which can be summarized in the following
sections as follows:
SECTION - I : Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)
- 8-methyl-1H-imidazo[1,2-a]pyridine-3-yl)-4-aryl pyrimidine-
2(H)-one.
SECTION - II : Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)
- 8-methyl-1H-imidazo[1,2-a]pyridine- 3-yl)- 4-aryl pyrimidine-
2(H)-thione.
SECTION – III : Synthesis and therapeutic evaluation of 4-(2-(4-chlorophenyl)
- 8-methyl-1H-imidazo[1,2-a]pyridine-3-yl)- 6-aryl pyrimidine-
2-amine.
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INTRODUCTION
Oxopyrimidines represent one of the most active class of compounds
possessing a wide spectrum of biological activities, such as significant in vitro
activity against unrelated DNA and RNA viruses including polio and Herpes viruses,
diuretic, Antitubercular spermicidal, etc.
R =Substituted Phenyl
Where,NNH
O
R1 R
R1 = Substituted Aryl
SYNTHETIC ASPECT :
Different methods are available in literature.
1. By the condensation of β–keto esters with N- Substituted urea.
2. By the condensation of β-dintriles with urea.
3. By the reaction of β- aldehydo nitrile with formamidine and urea.
4. By substituted benzaldehyde and substituted acetophenone were
subjected to the Claisen-Schmidt condensation in the presence of alkali
alcoholate and and yielded 1-(1-naphthyl)-3-aryl-prop-2-en-1-ones.
Compounds reacted with an alcohol solution of Urea in aqueous sodium
hydroxide to yield the corresponding 2-Oxopyrimidines.298
ArCHO
+
ArCOCH3
R R1
O
Urea
AlcoholMethanol
NaOH
NHN
R1R
O
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PHARMACEUTICAL IMPORTANCE
In recent years, dihydropyrimidinones and their derivatives have received
considerable attention in natural and synthetic organic chemistry because of their
therapeutic and pharmacological properties.299-306
Oxopyrimidine derivatives have wide variety of uses. In particular as
biologically active compounds in medicine
1. Antihypertensive299-302
2. α-1a-antagonists299-302
3. Neuropeptide Y antagonists.299-302
4. HIV gp-120-CDA inhibitors 299-302
5. Antibacterial303-306
Due to various biodynamic activities of pyrimidines and with a view to
have potent therapeutic agents, the synthesis of 6-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-4-aryl pyrimidine-2(H)-one have been undertaken by the
condensation of different substituted chalcones with urea in basic medium.
The constitution of the products have been delineated by elemental analyses,
IR, 1H NMR and Mass spectral data. The products were assayed for their in vitro
biological assay like antibacterial activity toward A. niger.
Looking to the interesting biological properties of oxopyrimidine it is
worthwhile to prepare some new derivative of oxopyrimidine bearing different
heterocyclic systems of medicinal value in order to achieve better therapeutic
agents. It has been described in the following section-I.
Section-I : Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)-8-
methyl-1H-imidazo[1,2-a]pyridine-3-yl)-4-aryl pyrimidine-2(H)-one.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-ONE.
Oxopyrimidine derivatives synthesized by condensation of (2z)-3-[2-(4-
chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one with urea
in basic media and methanol as a solvents.
Where,
N
N
Cl
CH3
N
NH
R
O
R = Aryl
The constitution of the synthesised products have been characterized using
elemental analyses, Infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards A. niger at a concentration 40μg. The biological 
activities of synthesized compounds recorded in table.
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REACTION SCHEME
R=Aryl
Where,
N
N
Cl
CH3
N
NH
R
O
N
N
Cl
CH3
R
O
N
N
Cl
CH3
CHO
10% KOH R
CH3
O
NaOH Urea
Methanol
Where,
R = Aryl
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IR SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-ONE.
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INSTRUMENT :SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2918 2975-2950 143-a
-CH3 C-H str.(sym.) 2852 2880-2860 ”
C-H i.p.def 1475 1470-1435 ”
C-H o.o.p.def. 1361 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1517 1520-1480 ”
C-H i.p.def 1015 1070-1000 ”
C-H o.o.p.def. 820 835-810 ”
Moiety C=N str. 1587 1610-1590 143-c
C-N str. 1176 1230-1020 ”
C-Cl str. 794 800-750 ”
Pyrimidine -NH str.(sym.) 3394 3450-3350 143-d
C=O str. 1658 1700-1640 ”
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NMR SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-ONE.
Internal Standard ; TMS ; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.40 3H singlet Ar-CH3
2 3.95 3H singlet Ar-OCH3
3 5.40 1H singlet Ar-Hh
4 7.20 1H triplet Ar-Hd
5 6.95 2H doublet Ar-H(a,a')
6 7.00 2H doublet Ar-H(b,b')
7 7.53 2H doublet Ar-H(f,f')
8 7.45 2H doublet Ar-H(g,g')
9 7.30 1H doublet Ar-Hc
10 8.07 1H doublet Ar-He
11 8.00 1H singlet -NH-
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MASS SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-ONE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-4-(4-methoxyphenyl)pyrimidine-2(H)-one.
[A] Preparation of 2-chloro-1-(p-chlorophenyl)ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2- (p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-aryl prop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of 6-(2-(4-chlorophenyl)-8-methyl-1H-imidazo[1,2-a]pyridine
-3-yl)-4-(4-methoxyphenyl)pyrimidine-2(H)-one.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one.(4.02gm,0.01m) and Urea (0.60gm,0.01m) was refluxed in
methanol for 6-8 hrs. NaOH is used as catalyst. The contents were poured on to
crushed ice and product isolated was crystallized from di-chloromethane. Yield 59%
(2.60gm) ; m.p.177 °C ; (C25H19ClN4O ; Found : C,67.78%;H,4.30%;N,12.60% ;
Required : C,67.80%;H,4.32%;N,12.65%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Oxopyrimidines derivatives have been obtained. The physical
data are recorded in Table No.- 2(IB).
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[F] Antimicrobial activity of 6-(2-(4-chlorophenyl)-8-methyl-1H-imidazo
[1,2-a]pyridine-3-yl)- 4-aryl pyrimidine-2(H)-one.
Antimicrobial testing was carried out as described in part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 2(IA).
TABLE NO.- 2(IA) BIOLOGICAL SCREENING OF 6-(2-(4-CHLOROPHENYL
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-ONE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
2(Ia) C6H5- 16 15 14 13 17
2(Ib) 4-CH3-C6H4 - 14 13 13 14 15
2(Ic) 4-OCH3 -C6H4- 16 14 15 16 13
2(Id) 4-Cl-C6H4 - 19 18 16 17 14
2(Ie) 4-F-C6H4 - 15 14 13 16 13
2(If) 4-Br-C6H4 - 14 13 15 13 14
2(Ig) 4-NH2-C6H4 - 16 15 14 14 15
2(Ih) 4-NO2-C6H4 - 14 13 12 15 16
2(Ii) 4-OH-C6H4 - 18 17 17 19 18
Stdn Ampicillin 21 20 23 22 -
” Amoxicillin 23 21 20 22 -
” Ciprofloxacin 24 23 22 21 -
” Norfloxacin 22 22 24 23 -
” Greseofulvin - - - - 23
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TABLE NO.- 2(IB) PHYSICAL CONSTANTS OF 6-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-ONE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
2(Ia)
2(Ib)
2(Ic)
2(Id)
2(Ie)
2(If)
2(Ig)
2(Ih)
2(Ii)
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C24H17ClN4O
C25H19ClN4O
C25H19ClN4O2
C24H16Cl2N4O
C24H16ClFN4O
C24H16ClBrN4O
C24H18ClN5O
C24H16ClN5O3
C24H17ClN4O2
412.0
426.0
442.5
446.0
430.0
490.0
427.0
457.0
428.0
165.0
175.0
177.0
170.0
162.0
155.0
169.0
180.0
172.0
0.54
0.56
0.55
0.56
0.53
0.59
0.57
0.56
0.52
52.0
55.0
59.0
60.0
54.0
57.0
58.0
61.0
58.0
13.57
13.12
12.65
12.53
13.00
11.39
16.37
15.30
13.06
13.50
12.90
12.60
12.40
12.97
11.00
16.35
15.19
13.02
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION
Thiopyrimidine derivatives first primary synthesise from aliphatic fragments
was carried out by Frankland and Kolbs in 1848. Since then a many distinct primary
synthetic method have been derived.307-316 It is also possible to prepare from other
heterocyclic compounds.317-320
N
N S
M
R1
R2
R4
R3
M = Sub. Ph
R1 = H, NO2
R2 = H, alkyl
R3 = H, alkyl
R4 = amino cycloalkyl
Selective antagonists for human α/A receptors
SYNTHETIC ASPECT :
Different methods are available in literature.
1. By the condensation of β–keto esters with N-methyl thiourea.321
2. By the condensation of β-dintriles with thiourea and gaunidines.322-324
3. By the reaction of β- aldehydo nitrile with formamidine and thiourea.325-
326
4. By the condensation of β- keto esters with amidino acetamide.327
PHARMACEUTICAL IMPORTANCE
Thiopyrimidine derivatives have wide variety of uses. In particular as
biologically active compounds in medicine, so thiopyrimidine derivatives play a vital
role in many biological processes and as synthetic drugs.
1. Antifungal328
2. Anticancer329,330,331
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3. Antitumor332
4. Cellobiase activity333
5. Antimicrobial334
6. Antineoplastic335
7. Antibacterial336,337
8. Antiinflammatory338,339
9. Antibiotics340
10. Antiviral341,342
11. Insecticidal343
12. Antifilarial344
13. Anti AIDS345
14. Antitubercular346
15. Antagonist347
16. Analgesic348
Thiopyrimidine derivatives as a antibacterial and fungicidal drugs ( I ), ( II )
reported by Kashima349 and ( III ) reported by Naik S. K.350
N
N
H
S
R
R1
N
N
H
R
R1 S
N
N
R
R1
R2
S
( I ) ( II ) ( III )
R,R1,R2= alkyl R,R1= alkyl R,R1= aryl
Guseva N. N. and co-workers351 prepared fungicidal active thiopyrimidine
derivative. (IV)
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N
N
H
S
OHCH3
CH3
CH3
R
( IV ) R = aryl
Saneyoshi, Mineo, Wakayama and co-workers352 have prepared 3’-amino-2-
thiopyrimidine nucleosides as anticancer drugs. (V)
N
N
NH2
S
OH2N
H2N X
Y
X= H, OH
Y= H, Me
( V )
C. J. Shishoo and K. S. Jain353 have prepared thiopyrimidine derivative as a
A2 receptor antagonists. (VI)
N
N
N
N
H
CH3COOH2CO
O
S
CH3
NH
CH3
( VI )
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M.A. Salama and S. A. El Essa354, have prepared substituted tetrahydro
thiopyrimidine derivative as a antimicrobial activity. (VII)
N
H
NH
S
O
O
H
H
H
Ar
Ar
( VII)
Looking to the interesting biological properties of thiopyrimidine it is
worthwhile to prepare thiopyrimidine bearing different heterocyclic systems of
medicinal value in order to achieve better therapeutic agents. It has been described
in the following section-II.
Section-II : Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)-8-
methyl-1H-midazo[1,2-a]pyridine-3-yl)-4-aryl pyrimidine-2(H)-thione.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 6-(2-(4-CHLOROPHENYL)-8-
METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-THIONE.
Thiopyrimidines represent one of the most active class of compounds
possessing a wide spectrum of biological activities, such as significant in vitro
activity against unrelated DNA and RNA viruses including polio and herpes
viruses, diuretic, antitubercular, spermicidal, etc. In view of these facts, It was
contemplated to synthesize thiopyrimidine derivatives by condensation of (2z)-3-
[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one with
thiourea in basic media and methanol as a solvents.
R = Aryl
Where,
N
N
Cl
CH3
N
NH
R
S
The constitution of the synthesized products have been characterized using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards A. niger at a concentration 40μg. The biological 
activities of synthesized compounds recorded in table.
Thiopyrimidine…..80
REACTION SCHEME
N
N
Cl
CH3
R
O
R= Aryl
Where,
NaOH
Methanol
Thiourea
Where,
R= Aryl
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
N
N
CH3
Cl
N
NH
R
S
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IR SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL-1H-IMIDAZO
[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-THIONE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2922 2975-2950 143-a
-CH3 C-H str.(sym.) 2854 2880-2860 ”
C-H i.p.def 1442 1470-1435 ”
C-H o.o.p.def. 1391 1395-1370 ”
Aromatic C-H str. 3088 3090-3030 143-b
C=C Str. 1498 1520-1480 ”
C-H i.p.def 1178 1125-1090 ”
C-H o.o.p.def. 833 835-810 ”
Moiety C=N str. 1600 1610-1590 143-c
C-N str. 1178 1230-1020 ”
C-Cl str. 800 800-750 ”
Pyrimidine C=S str.(asym) 1259 1275-1190 143-d
C=S str.(sym.) 735 700-600 ”
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NMR SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL
-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-
THIONE.
Internal Standard ; TMS; Solvent :CDCl3; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.44 3H singlet Ar-CH3
2 3.95 3H singlet Ar-OCH3
3 5.42 1H singlet Ar-Hh
4 7.20 1H triplet Ar-Hd
5 7.00 2H doublet Ar-H(a,a')
6 7.05 2H doublet Ar-H(b,b')
7 7.50 2H doublet Ar-H(f,f')
8 7.45 2H doublet Ar-H(g,g')
9 7.30 1H doublet Ar-Hc
10 8.05 1H doublet Ar-He
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MASS SPECTRAL STUDIES OF 6-(2-(4-CHLOROPHENYL)-8-METHYL
-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)PYRIMIDINE-2(H)-
THIONE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of 6-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-4-(4-methoxyphenyl)pyrimidine-2(H)-thione.
[A] Preparation of 2-chloro-1-(p-chlorophenyl) ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methylimidazo[1,2-a]pyridine
-3-yl]-1-aryl prop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of 6-(2-(4-chlorophenyl)-8-methyl-1H-imidazo[1,2-a]pyridine
- 3- yl)-4-(4-methoxyphenyl)pyrimidine-2(H)-thione.
A mixture (2z)-3-[2-(4-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one.(4.20gm,0.01m) and Thiourea (0.76gm,0.01m) was refluxed in
methanol for 6 hrs. NaOH is used as catalyst. The contents were poured on to
crushed ice and product isolated was crystallized from di-chloromethane. Yield 63%
(3.0gm) ; m.p.187 °C ; (C25H19ClN4OS ; Found : C,65.25%;H,4.10%;N,12.15% ;
Required : C,65.42%;H,4.17%;N,12.21%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Thiopyrimidines derivatives have been obtained. The physical
data are recorded in Table No.- 2(IIB).
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[F] Antimicrobial activity of 6-(2-(4-chlorophenyl)-8-methyl-1H-imidazo
[1,2-a]pyridine-3-yl)-4-aryl pyrimidine-2(H)-thione.
Antimicrobial testing was carried out as described in part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 2(IIA).
TABLE NO.- 2(IIA) BIOLOGICAL SCREENING OF 6-(2-(4-CHLOROPHENYL)-8-
METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-THIONE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
2(IIa) C6H5- 16 15 16 18 16
2(IIb) 4-CH3-C6H4 - 15 14 12 13 14
2(IIc) 4-OCH3 -C6H4- 14 13 15 12 13
2(IId) 4-Cl-C6H4 - 16 17 14 16 18
2(IIe) 4-F-C6H4 - 15 16 12 14 14
2(IIf) 4-Br-C6H4 - 13 12 13 14 15
2(IIg) 4-NH2-C6H4 - 15 13 14 12 16
2(IIh) 4-NO2-C6H4 - 12 14 12 14 15
2(IIi) 4-OH-C6H4 - 17 16 18 17 16
Stdn Ampicillin 20 21 22 21 -
” Amoxicillin 22 23 21 20 -
” Ciprofloxacin 23 22 24 22 -
” Norfloxacin 21 24 22 23 -
” Greseofulvin - - - - 25
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TABLE NO.- 2(IIB) PHYSICAL CONSTANTS OF 6-(2-(4-CHLOROPHENYL)-8-
METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL PYRIMIDINE-2(H)-THIONE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
2(IIa)
2(IIb)
2(IIc)
2(IId)
2(IIe)
2(IIf)
2(IIg)
2(IIh)
2(IIi)
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C24H17ClN4S
C25H19ClN4S
C25H19ClN4OS
C24H16Cl2N4S
C24H16ClFN4S
C24H16ClBrN4S
C24H18ClN5S
C24H16ClN5O2S
C24H17ClN4OS
428.0
442.0
458.0
462.0
446.0
506.0
443.0
473.0
444.0
173.0
182.0
187.0
175.0
160.0
166.0
171.0
175.0
158.0
0.54
0.58
0.56
0.57
0.44
0.60
0.55
0.56
0.49
59.0
56.0
63.0
60.0
65.0
57.0
55.0
67.0
54.0
13.06
12.65
12.21
12.09
12.54
11.03
15.78
14.78
12.59
13.02
12.62
12.15
11.98
12.50
11.00
15.75
14.70
12.46
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION
Amino pyrimidine is the most important member of all the diazine as this
ring system occurs widely in living organisms. Pyrimidine was first isolated by
Gabriel and Colman in 1899. 2-Amino pyrimidine and its derivatives represent
one of the most active class of compounds possessing a wide spectrum of
biological activities.
Pyrimidine and its derivatives have gained prominence because of their
potential pharmaceutical values. They are among those molecules that make life
possible as being some of the building blocks of DNA and RNA. Pyrimidine is
considered to be a resonance hybrid of the charged and uncharged canonical
structures, its resonance energy has been found to be less than benzene or
pyridine.
R=Substituted Phenyl
Where,
R1
NN
R
NH2 R1= Substituted Aryl
SYNTHETIC ASPECT :
Different methods are available in literature.
1. By the condensation of β–keto esters with N- Substituted guanidine321.
2. By the condensation of β-dintriles with gaunidines322-324.
3. By the reaction of β- aldehydo nitrile with formamidine and guanidine 325-326.
4. By substituted benzaldehyde and Substituted Acetophenone were subjected to
the Claisen-Schmidt condensation in the presence of alkali alcoholate and and
yielded 1-(1-naphthyl)-3-aryl prop-2-en-1-ones. Compounds reacted with an
alcohol solution of Guanidine hydrochloride in aqueous sodium hydroxide to yield
the corresponding 2-Aminopyrimidines.298
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ArCHO
+
ArCOCH3
R R1
O NN
R R1
NH2
Gaunidine
HCl
Alcohol
Methanol
NaOH NaOH
MECHANISM :
R R1
O
+
NH2 NH2
NH
NH
R1
NH
R
O
NH2
Alkali
NHNH
R
NH
OH
R1
NN
R
NH2
R1
NN
R
NH2
R1
Protontransfer
OH -
H+
H-
-
-
PHARMACEUTICAL IMPORTANCE
Aminopyrimidine derivatives have wide variety of uses. In particular as
biologically active compounds in medicine
1 Antitumor
2 Cellobiase activity
3 Antimicrobial
4 Antineoplast
5 Antibacterial
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6 Antiinflammatory
7 Antibiotics
8 Antiviral
9 Insecticidal
10 Antagonist298
11 Analgesic
12 Antifungal
Due to various biodynamic activities189-248 of pyrimidines and with a view to
have potent therapeutic agents, the synthesis of 4-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-6-aryl pyrimidine-2-amine have been undertaken by the
condensation of different substituted Chalcones with Guanidine hydrochloride in
basic Medium.
The constitution of the products have been delineated by elemental analyses,
IR, 1H NMR and further supported by Mass spectroscopy. The products were
assayed for their in vitro biological assay like antibacterial activity towards
Looking to the interesting biological properties of Aminopyrimidine it is
worthwhile to prepare Aminopyrimidine bearing different heterocyclic systems of
medicinal value in order to achieve better therapeutic agents. It has been described
in the following section-III.
Section-III : Synthesis and therapeutic evaluation of 4-(2-(4-chlorophenyl)-8-
methyl-1H-imidazo[1,2-a]pyridine-3-yl)-6-aryl pyrimidine-2-amine.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 4-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-6-ARYL PYRIMIDINE-2-AMINE.
Looking to the interesting pharmacological and agriculture activity of
pyrimidine ring system, it was considered worthwhile to synthesise. Amino
pyrimidine derivatives synthesized by condensation of (2z)-3-[2-(4-chlorophenyl)
-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-aryl prop-2-en-1-one with guanidine
hydrochloride in basic media and methanol as a solvent for study their biological
activities.
R = Aryl
Where,
N
N
Cl
CH3
N
N
R
NH2
The constitution of the synthesized products have been characterized using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards A. Niger at a concentration 40μg. The biological 
activities of synthesized compounds recorded in table.
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REACTION SCHEME
N
N
Cl
CH3
R
O
R= Aryl
Where,
NaOH
Methanol
Guanidine HCl
Where,
R= Aryl
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
N
N
CH3
Cl
N
N
R
NH2
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IR SPECTRAL STUDIES OF 4-(2-(4-CHLOROPHENYL)-8-METHYL-1H-IMIDAZO
[1,2-a]PYRIDINE-3-YL)-6-(4-METHOXYPHENYL)PYRIMIDINE-2-AMINE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2925 2975-2950 143-a
-CH3 C-H str.(sym.) 2880 2880-2860 ”
C-H i.p.def 1450 1470-1435 ”
C-H o.o.p.def. 1386 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1504 1520-1480 ”
C-H i.p.def 1041 1070-1000 ”
C-H o.o.p.def. 825 835-810 ”
Moiety C=N str. 1620 1610-1590 143-c
C-N str. 1190 1230-1020 ”
C-Cl str. 756 800-750 ”
Pyrimidine N-H str.(sym) 3448 3450-3350 143-d
C-N str. 1190 1220-1020 ”
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NMR SPECTRAL STUDIES OF 4-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-6-(4-METHOXYPHENYL)PYRIMIDINE-2-AMINE.
Internal Standard ; TMS; Solvent :CDCl3; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.30 3H singlet Ar-CH3
2 3.80 3H singlet Ar-OCH3
3 7.40 1H triplet Ar-Hd
4 6.90 2H doublet Ar-H(a,a')
5 7.10 2H doublet Ar-H(b,b')
6 7.75 2H doublet Ar-H(f,f')
7 7.60 2H doublet Ar-H(g,g')
8 7.00 1H doublet Ar-Hc
9 7.95 1H doublet Ar-He
10 7.50 1H singlet Ar-Hh
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MASS SPECTRAL STUDIES OF 4-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)-6-(4-METHOXYPHENYL)PYRIMIDINE-2-AMINE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of 4-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-6-(4-methoxyphenyl)pyrimidine-2-amine.
[A] Preparation of 2-chloro-1-(p-chlorophenyl) ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-aryl prop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of 4-(2-(4-chlorophenyl)-8-methyl-1H-imidazo[1,2-a]pyridine
- 3- yl)-6-(4-methoxyphenyl)pyrimidine-2-amine.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methy imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one.(4.02gm,0.01m) and Guanidine hydrochloride (0.59gm,0.01m)
was refluxed in methanol for 6-8 hrs. NaOH is used as catalyst. The contents were
poured on to crushed ice and product isolated was crystallized from di-chloro
methane. Yield 61% (2.9gm); m.p.165 °C; (C25H20ClN5O; Found:C,67.85%;H,4.55%;
N,15.83% ; Required : C,67.95%;H,4.56%;N,15.85%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Aminopyrimidines derivatives have been obtained. The
physical data are recorded in Table No.- 2(IIIB).
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[F] Antimicrobial activity of 4-(2-(4-chlorophenyl)-8-methyl-1H-imidazo
[1,2-a]pyridine-3-yl)-6-aryl pyrimidine-2-amine.
Antimicrobial testing was carried out as described in Part- I Experimental
Section [E] Page No. 38 . The zone of inhibition of the test solution are recorded in
Table No.- 2(IIIA).
TABLE NO.- 2(IIIA) BIOLOGICAL SCREENING OF (4-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-6-ARYL PYRIMIDINE-2-AMINE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
2(IIIa) C6H5- 18 17 15 17 15
2(IIIb) 4-CH3-C6H4 - 16 15 13 14 14
2(IIIc) 4-OCH3 -C6H4- 15 14 15 13 12
2(IIId) 4-Cl-C6H4 - 17 18 18 16 17
2(IIIe) 4-F-C6H4 - 16 15 14 15 14
2(IIIf) 4-Br-C6H4 - 14 13 15 14 13
2(IIIg) 4-NH2-C6H4 - 16 14 13 15 12
2(IIIh) 4-NO2-C6H4 - 13 15 14 14 16
2(IIIi) 4-OH-C6H4 - 20 19 17 16 19
Stdn Ampicillin 21 21 22 22 -
” Amoxicillin 23 23 21 21 -
” Ciprofloxacin 24 22 24 23 -
” Norfloxacin 22 24 23 23 -
” Greseofulvin - - - - 24
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TABLE NO.- 2(IIIB) PHYSICAL CONSTANTS OF (4-((2-(4-CHLOROPHENYL)
- 8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-6-ARYL PYRIMIDINE-2-AMINE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
2(IIIa)
2(IIIb)
2(IIIc)
2(IIId)
2(IIIe)
2(IIIf)
2(IIIg)
2(IIIh)
2(IIIi)
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C24H18ClN5
C25H20ClN5
C25H20ClN5O
C24H17Cl2N5
C24H17ClFN5
C24H17ClBrN5
C24H19ClN6
C24H17ClN6O2
C24H18ClN5O
411.0
425.0
441.0
445.0
429.0
489.0
426.0
456.0
427.0
162.0
170.0
165.0
159.0
152.0
149.0
160.0
168.0
156.0
0.56
0.58
0.55
0.53
0.52
0.60
0.55
0.56
0.50
59.0
56.0
61.0
59.0
55.0
57.0
58.0
60.0
54.0
17.00
16.44
15.85
15.69
16.29
14.27
19.69
18.39
16.37
16.97
16.37
15.83
15.62
16.18
14.26
19.60
18.35
16.31
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION
Cyclohexenone is the parent of a series of compounds that is important in
agricultural and medicinal chemistry. Cyclohexenones are derivatives of cyclo
hexane with carbonyl group at 1-position and double bond at 2-position (I).
Cyclohexenones can be conveniently synthesised by the treatment of α,β -
unsaturated carbonyl compounds with ethylacetoacetate in basic media.
O
( I )
In recent years cyclohexenone derivatives have gained lots of interest
because of its prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the synthesis of cyclohexenone derivatives have been
described in literature.355-361
1. N. Nanjundaswami et al.362 have prepared 6,7-dimethoxy-1-aryl-4-oxo-2-
naphthoate derivatives (III) by the reaction of dimethoxyphenyl aryl ketone
with diethyl succinate in presence of t-potassium butoxide.
H3CO
H3CO
R
O
COOEt
COOEt
t-BuOK
H3CO
H3CO
R
COOEt
O
(III)
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2. Michael addition of chalcone with active methylene compound such as
diethyl malonate, nitro methane and ethyl aceto acetate catalyzed by
potassium hydroxide in anhydrous ethanol results Michael adducts in
75–98% yield under ultrasound irradiation in 25–90 min.363
O
X
R1
R2
+
KOH
Ethanol
at 25-30°C
X
O
EtOOC
MECHANISM
+
+ +
R
O
CH3 R CH
+
CH
-
O
CH3
CH3
O
COOEt
CH3
O
CH
-
COOEt
H
+OH
-
A
A H
+
R CH
+
O
CH3
EtOOC CH
-
CH3
O
-H2O
CH3
O
R
EtOOC
CH3
O
R
O
EtOOC CH3
B
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The addition reaction between ethylacetoacetate and α,β-unsaturated ketone
give cyclohexenone via. Michael addition. This reaction has been carried out in
basic media by using sodium ethoxide or anhy. K2CO3 in acetone. During the
reaction nucleophillic addition of carbanion take place to the C=C of the acceptor.
The α,β-unsaturated compound is known as acceptor and ethylacetoacetate is
known as donor.
THERAPEUTIC EVALUATION
Cyclohexenones and its derivatives are widely used in pharmaceutical
industry. Considerable interest has been shown in the chemistry of cyclohexenones
due to their wide spectrum of therapeutic activities which can be listed as under.
1. Herbicidal364
2. Analgesic365
3. Antiinflammatory366
4. Anticonvulsant367
5. Antibacterial368
6. Antithrombitics369
7. Antagonist370
8. Antibiotic371,372
9. Cardiovascular373
Cyclohexenone derivatives which possess plant growth regulatory activity
have been reported.374,375 Nagao et al.376 have reported antiarrhythmic cyclo-
hexenones. Collins and co-workers377 have documented cyclohexenone derivatives
which possess estrogenic activity. Tvanov et al.378 have reported antimicrobial
activity of some cyclohexenone derivatives. V. K. Ahluwalia and co-workers379 have
assessed cyclohexenone derivatives for anti HIV-I, gastric secretion inhibitors and
pesticidal activity. Cyclohexenone derivatives have been reported to be active as
allergy inhibitors, platelet aggregation inhibitors and fibrinogen antagonist.380
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Rheinheimer J. et al.381 have synthesised 5-(dioxabicyclohept-6-yl) cyclo-
hexenone oxime ethers as herbicides and plant growth regulators. Harimaya and
co-workers382 have synthesised new cyclohexenone derivatives possessing
progesteron receptor binding inhibitory activity. The herbicidal activity of
cyclohexenone derivatives (IV) has been investigated.383
O
CH3
O
CH3
CH3
Cl
Cl
O
OH
CH3
(IV)
Antimicrobial activity of cyclohexenone derivatives has been studied by
Salama and Atshikh384. Takehiro and co-workers385 have reported cyclohexenones
possessing neutropeptide γ-receptor antagonist activity. Kimura and co-workers386
have prepared cyclohexenones which possess inhibitory activity of penienone and
they exhibit the remarkable inhibitory activity against the growth of lettuce seedlings.
Broughton H. et al.387 have demonstrated cyclohexenones as GABA α5 receptor
ligands for enhancing cognition properties.
Hermann S. et al.388 have reported cyclohexenones as herbicides.
Anticonvulsant activity of some cyclohexenone derivatives (V) have been reported
by Natalie D. et al.389 Bastiaan and co-workers390 have synthesised novel
cyclohexenone derivatives (VI) which are useful in the treatment of perkinson's
disease. Cyclohexenones (VII) as anticancer and antiinflammatory agents have
been investigated.391
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NH
CH3
COOR
O
N
O
R'
O
N
R1
R
CH3
CH3
O
N
CH3
CH3
O
(V)
R,R'= Alkyl R,R'= Alkyl
(VI) (VII)
Moreover, H. H. Parekh and co-workers392 have synthesised 6-carbethoxy
-5-(4'-cinnamoyloxyphenyl)-3-aryl-2-cyclohexenones and all the products have
been evaluated for their antimicrobial activity. Zhang C. et al.393 have prepared
tricyclic heterocycles, containing furan and cyclohexenone nucleus for treating
hyperproliferative disorders. Under the high-speed vibration milling conditions,
K2CO3 was found to be a very efficient catalyst for the solvent-free Michael reactions
of 1,3-dicarbonyl compounds with chalcones,e.g., I (X=CH) and aza chalcones,e.g.,
I (X=N). In most cases, conventional side reactions were avoided and excellent
yields were achieved. The influences of other catalysts and the vibration frequency
on the Michael reaction were also investigated.394
With a view to getting better therapeutic agent, it was contemplated to
synthesised cyclohexenones bearing furan nucleus to enhance the overall activity of
resulting compounds, which have been described as under.
Synthesis and therapeutic evaluation of ethyl-6-(2-(4-chlorophenyl)-8-methyl
-1H-imidazo[1,2-a]pyridine-3-yl)-4-aryl-2-oxocyclohex-3-ene-carboxylate.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF ETHYL-6-(2-(4-CHLORO
PHENYL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL-2-OXOCYCLO
HEX-3-ENE CARBOXYLATE.
The growing potent literature of recent years demonstrates that the
cyclohexenone derivatives are used as better therapeutic agents. These findings
prompted us to synthesize a series of ethyl-6-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-4-aryl-2-oxocyclohex-3-ene-carboxylate. The synthesis
was carried out by the condensation of chalcones with ethylacetoacetate in
acetone.
N
N
Cl
CH3
R
O
R= Aryl
Where,
Acetone
Metyl/Ethyl/t-Butyl
aceto Acetate
Where,
R= Aryl
R1=Methyl,Ethyl,t-Butyl
N
N
CH3
Cl
R
O
COOR1
K2CO3
The constitution of the synthesized products have been characterized using
elemental analyses, IR and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg. The
biological activities of synthesized compounds were compared with standard drugs.
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REACTION SCHEME
N
N
Cl
CH3
R
O
R= Aryl
Where,
Acetone
Metyl/Ethyl/t-Butyl
aceto Acetate
Where,
R= Aryl
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
R1=Methyl,Ethyl, t-Butyl
N
N
CH3
Cl
R
O
COOR1
K2CO3
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IR SPECTRAL STUDIES OF ETHYL-6-(2-(4-CHLOROPHENYL)-8-METHYL-
1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)-2-OXOCYCLOHEX
-3-ENE-CARBOXYLATE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2974 2975-2950 143-a
-CH3 C-H str.(sym.) 2870 2880-2860 ”
C-H i.p.def 1465 1470-1435 ”
C-H o.o.p.def. 1371 1395-1370 ”
Aromatic C-H str. 3051 3090-3030 143-b
C=C Str. 1535 1520-1480 ”
C-H i.p.def 1157 1125-1090 ”
C-H o.o.p.def. 819 835-810 ”
Moiety C=N str. 1581 1610-1590 143-c
C-N str. 1028 1230-1020 ”
C-Cl str. 790 800-750 ”
Cyclo-
hexenone
C=O str. of ester 1733 1750-1725 143-d
C=O str. of
cyclohexenone
1706 1720-1690 ”
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NMR SPECTRAL STUDIES OF ETHYL-6-(2-(4-CHLOROPHENYL)-8-METHY-
1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)-2-OXOCYCLOHEX
-3-ENE-CARBOXYLATE.
Internal Standard ; TMS; Solvent : DMSO; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.30 3H singlet Ar-CH3
2 3.80 3H singlet Ar-OCH3
3 1.30 3H triplet Alk.-CH3
4 4.10 2H quatrate Alk.-CH2
5 6.30 1H singlet CHi
6 2.40 2H doublet CHh
7 4.00 1H quatrate CHj
8 3.21 1H singlet CHk
9 6.50 1H triplet Ar-Hd
10 6.90 2H doublet Ar-H(a,a')
11 7.10 2H doublet Ar-H(b,b')
12 7.70 2H doublet Ar-H(f,f')
13 7.55 2H doublet Ar-H(g,g')
14 7.05 1H doublet Ar-Hc
15 7.90 1H doublet Ar-He
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MASS SPECTRAL STUDIES OF ETHYL-6-(2-(4-CHLOROPHENYL)-8-METHYL-
1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-(4-METHOXYPHENYL)-2-OXOCYCLOHEX
-3-ENE-CARBOXYLATE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of ethyl-6-(2-(4-chlorophenyl)-8
- methyl-1H -imidazo[1,2-a]pyridine-3-yl)-4-(4-methoxyphenyl)-2-oxocyclohex-3-
ene carboxylate.
[A] Preparation of 2-chloro- 1-(p-chlorophenyl)ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2- (p-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine-3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-arylprop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of ethyl-6-(2-(4-chlorophenyl)-8-methyl-1H-imidazo[1,2-a]
pyridine-3-yl)-4-(4-methoxyphenyl)-2-oxocyclohex-3-ene-carboxylate.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a] pyridine-3-yl]-1-
aryl prop-2-en-1-one.(4.02gm,0.01m) and Ethylacetoacetate (1.30gm,0.01m) was
refluxed in Acetone for 6-8 hrs.K2CO3 is used as catalyst. The contents were poured
on to crushed ice and product isolated was crystallized from di-chloromethane. Yield
59% (3.05gm) ; m.p.163 °C ; (C30H27ClN2O ; Found : C,69.43%;H,5.21%;N,5.35% ;
Required : C,69.97%;H,5.28%;N,5.44%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Cyclohexenone derivatives have been obtained. The physical
data are recorded in Table No.- 3(B).
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[F] Antimicrobial activity of ethyl-6-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)-4-aryl-2-oxocyclohex-3-ene-carboxylate.
Antimicrobial testing was carried out as described in Part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 3(A).
TABLE NO.- 3(A) BIOLOGICAL SCREENING OF ETHYL-6-(2-(4-CHLORO
PHENYL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL-2-OXOCYCLO-
HEX-3-ENE-CARBOXYLATE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
3a C6H5- 18 17 15 17 16
3b 4-CH3-C6H4 - 15 16 14 15 15
3c 4-OCH3 -C6H4- 14 15 13 12 14
3d 4-Cl-C6H4 - 16 19 15 16 17
3e 4-F-C6H4 - 16 15 14 13 15
3f 4-Br-C6H4 - 15 12 13 14 14
3g 4-NH2-C6H4 - 14 13 15 12 13
3h 4-NO2-C6H4 - 13 15 14 14 16
3i 4-OH-C6H4 - 17 16 17 15 18
Stdn Ampicillin 20 22 21 22 -
” Amoxicillin 22 20 21 23 -
” Ciprofloxacin 23 24 22 22 -
” Norfloxacin 21 23 23 24 -
” Greseofulvin - - - - 24
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TABLE NO.- 3(B) PHYSICAL CONSTANTS OF ETHYL-6-(2-(4-CHLORO
PHENYL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)-4-ARYL-2-OXOCYCLO-
HEX-3-ENE-CARBOXYLATE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
3a
3b
3c
3d
3e
3f
3g
3h
3i
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C29H25ClN2O3
C30H27ClN2O3
C30H27ClN2O4
C29H24Cl2N2O3
C29H24ClFN2O3
C29H24ClBrN2O3
C29H26ClN3O3
C29H24ClN3O5
C29H25ClN2O4
484.0
498.0
514.0
518.0
502.0
562.0
499.5
529.0
500.0
160.0
161.0
163.0
155.0
150.0
152.0
159.0
157.0
149.0
0.58
0.57
0.56
0.52
0.53
0.60
0.54
0.53
0.49
58.0
54.0
59.0
61.0
57.0
55.0
60.0
56.0
58.0
5.78
5.61
5.44
5.39
5.57
4.97
8.40
7.93
5.59
5.71
5.60
5.35
5.35
5.55
4.90
8.37
7.89
5.56
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION :
The chemistry of Pyrazoline was reviewed by Jarboe in 1967. Pyrazoline has
three possible tautomeric structures, but the structure shown is the most stable
which can be prepared by hydrazine hydrate and acrolein.
NH2
NH2
CH2
CHO
+
N
N
H
The interesting biological activities of a novel heterocycle like pyrazolines
have stimulated considerable research work in recent years leading to the synthetic
utility of the derivatives of this ring system.
SYNTHETIC ASPECT :
Different methods for the preparation of 2-Pyrazolines are as per follows :
(1) The most common procedure for the synthesis of an aliphatic or aromatic
hydrazine with α, β - unsaturated carbonyl compounds.
N
N
R"
R1
RR
O
R1 NH
NH2
R''
+
(2) 3-Amino-2-Pyrazolines can be prepared by condentation of α, β -
unsaturated nitriles with hydrazine.
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N
N
Ar
H2C= CHCN + Ar – NHNH2
(3) 2 - Pyrazolines can also be synthesised by the condensation of chalcones
with hydrazine hydrate395.
(4) A solution of 0.002 mol of the corresponding chalcones 3a-C, 0.3 g (0.006
mol) of hydrazine hydrate and 10 ml of acetic acid was refluxed for 5
hours, then catalytic amount of HCI (4-5 drops) was added and yet
refluxed for 30 min. After cooling 30 ml water was added and the resulting
precipitate was filtered, washed with water.396
R
O
N
O
CH3
O
Acetic Acid
R
N
N
O
CH3
O
N
CH3
O
3a-C
5a-C
NH2NH2.H2O
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(5) Iodobenzene diacetate, a relatively nonmetallic oxidant, has been utilized
efficiently for the oxidation of N-substituted hydrazones of chalcones to
afford 1,3,5- trisubstituted pyrazoles under mild reaction conditions.397
REACTION MECHANISM :
The following mechanism seems for the condensation of chalcones with
hydrazine hydrate.
R R1
O
NH2
NH R2
Proton
transfer
R
O N
R1
R2 NH2N
H
N
R1
R
OH
R2
N N
R
R1
R2
(I) (II)
(IV) (III)
N
+R2
NH2H
CH3CH
-
CH3
O N
+R2
NH2H
CH3CH
-
CH3
OH
Nucleophillic attack by hydrazine at the β–carbon of the α,β–unsaturated
carbonyl system forms species (II), in which the negative charge is mainly
accommodated by the electronegative oxygen atom. Proton transfer from nitrogen to
oxygen produces an intermediate and which simultaneously ketonises to ketoamine
(III). Another intramolecular Nucleophillic attack by the primary amino group of
ketoamine on its carbonyl carbon followed by proton transfer from nitrogen to
oxygen lead ultimately to hydroxyl amine (IV). The later with a hydroxyl group and
amine group on the same carbon lose water easily to yield the pyrazolines.
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PHARMACEUTICAL IMPORTANCE :
2- Pyrazolines have been found to possess very interesting range of
important therapeutic activities shown below :
1. Bactericidal395
2. Anticonvulsant398
3. Diuretic399
4. Analgesic400
5. Antiinflammatoty401
6. Insecticidal402
7. Antibacterial403
8. Herbicidal404
3-N-Arylamino-1-(4,5,6,7-tetrahydro-thiazol-yl)-2-pyrazolines are found to be
useful as an antiinflammatory and allergy inhibitor agents.405 K. Trena and
Zolzislaw406 have tested 2-Pyrazolines on rats and observed comparatively good
response as hypoglycemic agents. Moreover, several pyrazolines have been
reported to possess antimicrobial activity407. Some new 2-pyrazolines (I) have been
synthesised and their antimicrobial properties have been reported by Koos et al.408
More over, use of some pyrazolines as cardiovascular agent along with their
synthesis409 is also reported in literature. Subbanward et al.410 have prepared and
tested some novel pyrazoline derivatives for their antimicrobial activity.
Recently Abl El-Latif and co-workers411 have synthesized pyrazoline
derivatives. Ismail et al.412 have prepared pyrazoline derivatives bearing
sulphonamide moiety and tested their antimicrobial activity. Sarah and co-
workers413 have synthesised pyrazoline derivatives and reported antibacterial,
analgesic and antiinflammatory activities. Wang et al.414 have synthesised
pyrazoline derivatives which showed bactericidal activity.
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4,5-Dihydro-1,3-dimethyl- 5- (2,4,6-trimethyl- 2-cynohexan- 1-yl)-1H- pyrazole
and other derivatives are observed as versatile compounds having perfume
fragrance by D. Francois et al.415 F. Manna and co- workers416 have repoted
pyrazoline derivatives which act as potent antiinflammatory, analgesic and
antipyretics agent. Grant and co-worker417 found pyrazoline (II) having good
antimicrobial properties.
N
N
N
CH3
CH3
Cl
Ph
N N
R'
R
COOH
OH
( I ) ( II)
Jatin Upadhyay et al.418 have synthesised 1- actyl- 4,5-dihyro-5-(4-hydroxy
-3-methanoxyphenyl)-3-(4-phenylsulphonamidophenyl)-1H-pyrazole and other
derivatives. Vikani and co-workers419 have prepared pyrazoline derivatives from
arsanillic acid for their antimicrobial and antifungal activities. Patel et al.420 have
synthesised and reported antimicrobial activity of pyrazolines. Fernandes et al.421
have synthesised and tested for their activity against different strains of bacteria and
fungi. Sorathia et al.422 have reported new derivatives of pyrazoline as antimicrobial
agents.
More Udupi and co- worker423 have reported pyrazolines having analgesic,
bactericidal, antifungal, antitubercular and antiinflammatory agents. Moreover,
fungicidal, herbicidal and plant growth regulatory activity has also been observed by
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Kadu et al.424 and antimicrobial by patil et al.425 Thus interesting biological activities
of a novel heterocycles like pyrazolines have stimulated considerable research work
in recent years. In our search for new potential antimicrobial compounds, the
reaction of series of chalcone with hydrazine hydrate under different conditions
have been investigated and pharmacological profile of the compounds have been
studied and describes as under.
Synthesis and therapeutic evaluation of 2-(4-chlorophenyl)-3-(4,5-dihydro-3-
aryl-1H-pyrazol-5-yl)-8-methyl-1H-imidazo[1,2-a]pyridine.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-(4-CHLOROPHENYL)
- 3-(4,5-DIHYDRO- 3-ARYL-1H-PYRAZOL- 5-YL)- 8- METHYL-1H-IMIDAZO[1,2-a]
PYRIDINE.
Pyrazoline derivatives have attracted considerable attention as it appeared of
interest to possess wide range of therapeutic activities. With an attempt to getting
better therapeutic agents, pyrazolines of Type-I have been prepared by the
condensation of chalcone with hydrazine hydrate.
N
N
CH3
Cl
NH
N R
R = Aryl
Type-I
Where,
The constitution of the synthesized products has been characterized by using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40μg. The 
biological activities of the synthesized compounds have been compared with
standard drugs.
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REACTION SCHEME
N
N
Cl
CH3
RO R= Aryl
Where,
Methanol
N
N
CH3
Cl
NH
N R
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
Hydrazine Hydrate
R= Aryl
Where,
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IR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(4,5-DIHYDRO
- 3-(4-METHOXYPHENYL)-1H-PYRAZOL- 5-YL)- 8- METHYL-1H-IMIDAZO[1,2-a]
PYRIDINE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2968 2975-2950 143-a
-CH3 C-H str.(sym.) 2842 2880-2860 ”
C-H i.p.def 1483 1470-1435 ”
C-H o.o.p.def. 1389 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1483 1520-1480 ”
C-H i.p.def 1100 1125-1090 ”
C-H o.o.p.def. 831 835-810 ”
Moiety C=N str. 1595 1610-1590 143-c
C-N str. 1172 1230-1020 ”
C-Cl str. 785 800-750 ”
Pyrazoline C=N str. 1595 1655-1550 143-d
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NMR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(4,5-DIHYDRO
- 3-(4-METHOXYPHENYL)-1H-PYRAZOL- 5-YL)- 8- METHYL-1H-IMIDAZO[1,2-a]
PYRIDINE.
Internal Standard ;TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.30 3H singlet Ar-CH3
2 3.90 3H singlet Ar-OCH3
3 3.24 1H doublet CHh
4 3.80 1H doublet CHh'
5 3.65 1H triplet Ar-Hi
6 6.50 1H triplet Ar-Hd
7 6.90 2H doublet Ar-H(a,a')
8 7.10 2H doublet Ar-H(b,b')
9 7.75 2H doublet Ar-H(f,f')
10 7.60 2H doublet Ar-H(g,g')
11 7.00 1H doublet Ar-Hc
12 8.00 1H doublet Ar-He
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MASS SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(4,5-DIHYDRO
- 3-(4-METHOXYPHENYL)-1H-PYRAZOL- 5-YL)- 8- METHYL-1H-IMIDAZO[1,2-a]
PYRIDINE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of 2-(4-chlorophenyl)-3-(4,5-dihydro-3-
(4-methoxyphenyl)-1H-pyrazol-5-yl)-8-methyl-1H-imidazo[1,2-a]pyridine.
[A] Preparation of 2-chloro-1-(p-chlorophenyl)ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2-(p-chlorophenyl)- 8- methyl imidazo[1,2-a]pyridine-3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-aryl prop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of 2-(4-chlorophenyl)-3-(4,5-dihydro-3-(4-methoxyphenyl)
-1H-pyrazol-5-yl)-8-methyl-1H-imidazo[1,2-a]pyridine.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one. (4.02gm,0.01m) and hydrazine hydrate (0.32gm,0.01m) was
refluxed in methanol in acidic media for 6-8 hrs. The contents were poured on to
crushed ice and product isolated was crystallized from di-chloromethane. Yield 56%
(2.6gm); m.p.136 °C; (C24H21ClN4; Found : C,69.02%;H,4.95%;N,13.35%; Required :
C,69.14%;H,5.08%;N,13.44%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Pyrazoline derivatives have been obtained. The physical data
are recorded in Table No.- 4(B).
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[F] Antimicrobial activity of 2-(4-chlorophenyl)-3-(4,5-dihydro-3-aryl-1H-
pyrazol-5-yl)-8-methyl-1H-imidazo[1,2-a]pyridine.
Antimicrobial testing was carried out as described in part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 4(A).
TABLE NO.- 4(A) BIOLOGICAL SCREENING OF 2-(4-CHLOROPHENYL)-3-(4,5
-DIHYDRO-3-ARYL-1H-PYRAZOL-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
4a C6H5- 16 15 14 15 16
4b 4-CH3-C6H4 - 15 14 12 13 15
4c 4-OCH3 -C6H4- 13 12 15 14 12
4d 4-Cl-C6H4 - 17 16 18 16 19
4e 4-F-C6H4 - 15 14 16 13 15
4f 4-Br-C6H4 - 12 15 14 15 14
4g 4-NH2-C6H4 - 15 14 13 12 15
4h 4-NO2-C6H4 - 14 13 15 14 16
4i 4-OH-C6H4 - 18 19 16 17 15
Stdn Ampicillin 22 20 21 21 -
” Amoxicillin 21 22 23 22 -
” Ciprofloxacin 24 23 22 23 -
” Norfloxacin 23 24 24 23 -
” Greseofulvin - - - - 23
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TABLE NO.- 4(B) PHYSICAL CONSTANTS OF 2-(4-CHLOROPHENYL)-3-(4,5-
DIHYDRO-3-ARYL-1H-PYRAZOL-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
4a
4b
4c
4d
4e
4f
4g
4h
4i
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C23H19ClN4
C24H21ClN4
C24H21ClN4O
C23H18Cl2N4
C23H18ClFN4
C23H18ClBrN4
C23H20ClN5
C23H18ClN5O2
C23H19ClN4O
386.5
400.5
416.5
421.0
404.1
465.5
401.5
431.5
402.5
154.0
123.0
136.0
146.0
168.0
109.0
131.0
143.0
121.0
0.59
0.61
0.55
0.62
0.48
0.66
0.51
0.58
0.43
60.0
68.0
56.0
59.0
62.0
55.0
60.0
59.0
48.0
14.48
13.98
13.44
13.30
13.84
12.03
17.43
16.22
13.91
14.33
13.89
13.35
13.25
13.80
12.00
17.36
16.05
13.83
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION:
Isoxazole come under the class of compounds containing two heteroatom in
five membered ring, Oxygen and Nitrogen.
N
O
( I )
This type of structure (I) was first reported by Claisen for the product obtained
by the reaction of 1,3-Diketone with hydroxylamine.426 More work for Isoxazole was
done by Claisen and his students427,428 to provide solid foundation of Isoxazole
chemistry. Not only that, other scientist Cremlico gave important contribution to
understand Isoxazole chemistry. Isoxazoles shows typical properties of an aromatic
system, but under the conditions, particularly reducing or basic media, it becomes
highly labile.
SYNTHETIC ASPECT :
Isoxazoles may be prepared by reaction between hydroxylamine and α, β-
dicarbonyl compound. The reaction proceeds via the formation of an oxime, which
possibly undergoes cyclisation.
R-C-CH2-C-R
O O
NH2OH
OH
R
R
N
OH
N
O
R
R
OH
N
O
R
R-H2O
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Substituted Isoxazoles were prepared from hydroxylamine hydrochloride and
chalcones.429 Naik and co-workers430 have synthesised Isoxazoles by bromination of
chalcones, followed by cyclocondensation of the α,β-dibrominated, satd. Chalcones
with hydroxylamine hydrochloride in ethanol, in presence of KOH. Other method
was reported by El.Kholy et al.431 The Isoxazole of type (II) was prepared by the
reaction of ethyl-3-oxo-butanoate with malononitrile and ethyl cyano acetate.
N
O CH2X
CH3 COOEt
X=CN,COOEt
( II )
Chalcones of 2-(4'-chlorophenylamino)-4-(4'-fluorophenylamino)-6-(4'-acety
lphenylamino)-s-triazine have been synthesized by condensation with different
aromatic aldehydes. These chalcones on treatment with hydroxylamine
hydrochloride in presence of alkali give isoxazoles and on treatment with
malononitrile in presence of ammonium acetate give cyanopyridines.432
A series of 2,4-bis-(4'-chloro phenyl amino) -6- [4'-{1''- acetyl- 5''-aryl- 2''-
pyrazolin-3''-yl}phenyl amino]-s-triazines have been prepared by the reaction of
chalcone and hydrazine hydrate in presence of glacial acetic acid and 2,4-bis-
(4'-chlorophenylamino)-6-[4'-{5''-aryl-2''-isoxazol-3''-yl}phenylamino]-s-triazines were
similarly prepared with hydroxylamine hydrochloride in presence of alkali. All the
synthesized compounds have been screened for their antimicrobial activity. The
structure of synthesized compds. have been confirmed on the basis of elemental
anal., IR and 1H NMR spectral data.433
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PHARMACEUTICAL IMPORTANCE :
Isoxazoles shows various biological activities which are shown below.
1. Antiviral434
2. Herbicidal435
3. Nematocidal436
4. Anticonvulsant437
5. Central muscle relaxing438
6. Neuroleptic439
7. Anticholestermic440
B.Victor 441 have reported antipyretic antiarthitic and immunoregulating
activities of some Isoxazole derivatives. Herbicidal activity of some isoxazoles have
been reported by Alfred et al.442 and fungicidal activity observed by Mackie et al.443
Some Isoxazole derivatives have been prepared which showed broad spectrum of
physiological properties viz. antitumor444, antileukemia445, antiinflammatory446,
antimicrobial447 and anthelmintic448 activities.
Moreover Isoxazole have been prepared which showed broad spectrum of
activities viz. antitumor449 anthelmitic450 antiinflammatory451 antimicrobial452
antileukemia453 and herbicidal454. Recently, Isoxazole derivatives possessing
fungicidal455 and herbicidal456 properties are also reported. Rajeev Jain et al.457
prepared isoxazoles are hypoglycemic agents. Inani et al.458 synthesised isoxazoles
as an inflammation inhibitors and analgesics agents. A.R. Parikh459 and coworkers
have prepared isoxazoles as an antimicrobial agents. Masui et al.460 have prepared
isoxazoles having pesticidal activity. Some excellent herbicidal results obtained by
Reddy et al.461 Moreover, isoxazoles found to possess remarkable anxiolytic and
antihypertensive effect, reported by Nyitrai et al.462 Mishra et al.463 have synthesised
and reported isoxazoles as useful agents for analgesic and antiinflammatory
activities. Aicher et al.464 cited some Isoxazole derivatives possessing hypoglycemic
agents.
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Doshi Rajeev et al.465 have synthesised and screened antitubercular activity.
Some, isoxazoles are found to possess herbicidal466, potential antiinflammatory467
and antimicrobial agents.468
Cyclocondensation of (2E)-1-(3,5-Dibromo-4-methoxyphenyl)-3-aryl-prop-2-
en-1-ones on reaction with hydroxylamine hydrochloride in presence of acetic acid
and sodium acetate to give 3-(3,5-dibromo-4-methoxyphenyl)-5-aryl-isoxazoles. The
compounds were tested against different microbes for their antimicrobial activity and
antitubercular activity.469
5-(Substituted phenyl)-{3-[4-2-methyl-4-(4-hydroxybenzylidene)-5-oxoimidazo
-1-yl)]phenyl}-Isoxazole have been prepared by the refluxation for 10 hrs. of
4-(4-hydroxybenzylidene)-1-{4-[3-(substituted phenyl)prop-2-enoyl]phenyl}-2-methyl
imidazol-5-one with hydroxylamine hydrochloride and 40% potassium hydroxide
solution in dioxane. The intermediate 4-(4-hydroxybenzylidene)-1-{4-[3(substituted
phenyl)prop-2-enoyl]phenyl}-2-methyl-imidazol-5-one was synthesized by the
condensation of 1-(4-acetylphenyl)-4-(4-hydroxy benzyl idene)-2-methyl-3,5-dihydro
imidazol-5-one with various aldehydes.The antimicrobial activities of these
isoxazoles were also studied.470
Thus, significant biological properties associated with isoxazoles have
aroused considerable interest to design the compounds in which benzimidazole
moiety is incorporated. Such compounds have been synthesized and described as
under.
Synthesis and therapeutic evaluation of 2-(4-chlorophenyl)-3-(3-aryl-isoxazole-
5-yl)-8-methyl-1H-Imidazo[1,2-a]pyridine.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF 2-(4-CHLOROPHENYL)
-3-(3-ARYL-ISOXAZOLE-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Isoxazole derivatives have created interest in the field of medicinal chemistry,
due to wide rage of biological activities exhibited by them. Prompted by these facts,
the preparation of Isoxazole of type (III) was carried out by condensing chalcones
with hydroxylamine hydrochloride in the presence of sodium acetate.
N
N
CH3
Cl
O
N R
Where,
R= Aryl
Type (III)
The constitution of the synthesized products has been characterized by using
elemental analyses, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40μg. The 
biological activities of the synthesized compounds have been compared with
standard drugs.
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REACTION SCHEME
N
N
Cl
CH3
RO
R= Aryl
Where,
NaOH
Ethanol
N
N
CH3
Cl
O
N R
Where,
R= Aryl
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
NH4OH HCl
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IR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(3-(4-METHOXYPHENYL)
ISOXAZOLE-5-YL)-8 METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2970 2975-2950 143-a
-CH3 C-H str.(sym.) 2839 2880-2860 ”
C-H i.p.def 1460 1470-1435 ”
C-H o.o.p.def. 1398 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1508 1520-1480 ”
C-H i.p.def 1139 1125-1090 ”
C-H o.o.p.def. 831 835-810 ”
Moiety C=N str. 1610 1610-1590 143-c
C-N str. 1191 1230-1020 ”
C-Cl str. 783 800-750 ”
Isoxazole C=C str. 1538 1580-1550 143-d
C=N str. 1460 1470-1460 ”
N-O str. 850 850-810 ”
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NMR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(3-(4-METHOXY
PHENYL)ISOXAZOLE-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Internal Standard ; TMS; Solvent : DMSO; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.42 3H singlet Ar-CH3
2 3.86 3H singlet Ar-OCH3
3 6.95 1H singlet CHh
4 7.00 1H triplet Ar-Hd
5 7.35 2H doublet Ar-H(a,a')
6 7.50 2H doublet Ar-H(b,b')
7 7.90 2H doublet Ar-H(f,f')
8 7.75 2H doublet Ar-H(g,g')
9 7.05 1H doublet Ar-Hc
10 8.20 1H doublet Ar-He
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MASS SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-3-(3-(4-METHOXY
PHENYL)ISOXAZOLE-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of 2-(4-chlorophenyl)-3-(3-(4-methoxy
phenyl)isoxazole-5-yl)-8-methyl-1H-imidazo[1,2-a]pyridine.
[A] Preparation of 2-chloro-1- (p-chlorophenyl)ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2-(p-chlorophenyl)- 8- methyl imidazo[1,2-a]pyridine- 3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
-3-yl]-1-aryl prop-2-en-1-one.
See on Page No.38 Part-I (D)
[E] Preparation of 2-(4-chlorophenyl)-3-(3-(4-methoxyphenyl)isoxazole-5-yl)-
8-methyl-1H-imidazo[1,2-a]pyridine.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl] aryl
prop-2-en-1-one. (4.02gm,0.01m) and hydroxylamine hydrochloride (0.7gm, 0.01m)
was refluxed in ethanol for 11 hrs. NaOH is used as catalyst. The contents were
poured on to crushed ice and product isolated was crystallized from di-
chloromethane. Yield 63% (3.0gm); m.p.165 °C ; (C24H18ClN3O2; Found : C,69.15%;
H,4.24%; N,9.87%; Required : C,69.31%:H,4.36%;N,10.10%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Isoxazole derivatives have been obtained. The physical data
are recorded in Table No.- 5(B).
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[F] Antimicrobial activity of 2-(4-chlorophenyl)-3-(3-aryl-isoxazole-5-yl)-8-
methyl-1H-imidazo[1,2-a]pyridine.
Antimicrobial testing was carried out as described in part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 5(A).
TABLE NO.- 5(A) BIOLOGICAL SCREENING OF 2-(4-CHLOROPHENYL)-3-(3-
ARYL-ISOXAZOLE-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
5a C6H5- 17 18 19 16 18
5b 4-CH3-C6H4 - 14 15 13 14 15
5c 4-OCH3 -C6H4- 13 12 14 15 13
5d 4-Cl-C6H4 - 19 15 16 17 16
5e 4-F-C6H4 - 14 13 15 12 14
5f 4-Br-C6H4 - 13 14 12 15 13
5g 4-NH2-C6H4 - 15 13 14 13 12
5h 4-NO2-C6H4 - 12 14 15 14 15
5i 4-OH-C6H4 - 16 17 16 18 16
Stdn Ampicillin 20 22 21 21 -
” Amoxicillin 22 21 22 23 -
” Ciprofloxacin 23 24 24 23 -
” Norfloxacin 23 23 24 24 -
” Greseofulvin - - - - 23
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TABLE NO.- 5(B) PHYSICAL CONSTANTS OF 2-(4-CHLOROPHENYL)-3-(3-
ARYL-ISOXAZOLE-5-YL)-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
5a
5b
5c
5d
5e
5f
5g
5h
5i
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C23H16ClN3O
C24H18ClN3O
C24H18ClN3O2
C23H15Cl2N3O
C23H15ClFN3O
C23H15ClBrN3O
C23H17ClN4O
C23H15ClN4O3
C23H16ClN3O2
385.5
399.5
415.5
420.0
403.5
464.5
400.5
430.5
401.5
171.0
158.0
165.0
149.0
152.0
143.0
155.0
139.0
150.0
0.51
0.53
0.54
0.59
0.50
0.61
0.53
0.59
0.50
54.0
60.0
63.0
59.0
57.0
50.0
55.0
53.0
52.0
10.89
10.51
10.10
10.00
10.41
9.04
13.98
13.00
10.46
10.85
10.46
9.98
9.91
10.23
9.01
13.00
12.90
10.40
Solvent System : Ethyl acetate : Hexane (4:6)
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INTRODUCTION
The saturated Heterocyclic three-member ring containing one oxygen atom is
known as Oxirane ( I ). Oxirane and its derivatives have been known for a long time
and have been used as key intermediates in the synthesis of great variety of organic
compounds. The Oxirane ring has also designated as “epoxide”, “ethylene oxide”,
“ glycide” or some times as “α, β–epoxy ethane” and “1,2-oxido ethane”
Wurtz471 first discovered Oxirane or ethylene oxide in 1859.
( I )
O
SYNTHETIC ASPECT
There are so many procedures have been cited in the literature to synthesise
oxiranes.
( i ) The simplest method of preparing the parent compound oxirane is the direct
oxidation of alkene by air over a silver catalyst at elevated temperature or it’s
oxidation to epoxide can be usefully accomplished with organic per acids.472
Some times epoxidation is carried out by a more reagent alkaline H2O2.473
( ii ) Payne and co-workers474,475 have used a mixture of benzonitrile and H2O2 in
methanol which produces peroxy carboximidic acid which is an efficient
oxidizing agent.
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( iii ) Epoxidation can also been carried out by using sodium hypochloride
catalysed by transition metal complexes.476
( iv ) An excellent method for the introduction of an epoxide ring involves various
ring closure procedure. A major synthetic pathway of ring closure methods is
the Darzens condensation.477 For example, benzaldehyde is converted into
corresponding glycide described as under.478
C6H5CHO + ClCH2COOC(CH3)3
t-BuOK
t-BuOH
O
H5C6
O
O
CH3
CH3
CH3
( v ) Coreys and Chakowski479 discovered an ingenious application of dimethyl
sulfoxonium methylides as methylene transfer agents to the carbonyl group
for oxirane formation.
H5C6
O
C6H5 (H3C)2 S
O
CH2
-
O
O
C6H5
H5C6
( vi ) Rasaki Abayomi Osisany et al.480 have been synthesized chalcone epoxide
by using hydrogen peroxide in alkaline medium.
( vii ) Straub Thomas S. et al.481 reported that α, β - unsaturated carbonyl
compounds rapidly converted to epoxy ketones at room temp. in aqueous
sodium perborate in the presence of phase transfer catalyst.
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H3CO
O
R
H3CO
O
O
R
OH
H2O2
(Viii) An efficient epoxidation of chalcones with urea-hydrogen peroxide under
ultrasound irradn. was carried out in 78-93% yields. Compared with the
classical method, the advantages of protocol are to use a safer oxidant, mild
conditions, no toxic solvent and shorter reaction time.482
PHARMACEUTICAL IMPORTANCE :
The growing importance of epoxides in the field of natural product chemistry
indicates that epoxides from a part of a large number of naturally occurring
compounds.483 Epoxides have been known to form a part of terpens like linalool
epoxide484 (II) and also antitumor485 agent and antibiotics486 such as Stranmonin B
( III ) and Fumaglillin ( IV ).
CH3CH3
CH3 CH3
O O
CH3 CH3
O
O
O
OH
O
O
CH3
CH3
( IV )( II ) ( III )
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Moreover, Nomura Yutaka et al.487 synthesized epoxy succinic acid
derivatives which are useful in the prevention of treatement of bone diseases such
as osteoporosis, Malignant hyperalemia and in the treatment of osteoarthritis and
rheumatold arthritis. Kikkawa Kosi488 and co-workers synthesised epoxide
derivatives (V) which exhibited 100% herbicidal activity against panciu, crusgalli and
scirpus juncoides respectively with no damage on rice.
( V ) ( VI )
O
CH3
R
1
S N
CH3
N
R
2
R
1
O
Moder Kennteth Philip489 have reported epoxides ( VI ) as antiulcer agents.
Some oxirane carboxylic acid and esters are useful as intermediate for
hypoglycemics and hypolipeacics Rose Henry J.490 synthesised epoxide derivatives
having potent fungicidal activity. Some epoxides have been reported as insecticides
and pesticides. Hamaguchi Shigeki et. al.491 synthesized some optically active halo
methyl oxirane useful as insect pheromones. Neef Gunter and co-worker492
prepared Gonene epoxide and reported that it can be used as intermediates for
antigestanenes and antiglucocorticoides. Oesch F. et al.493 reported enzyme
inhibitor activity of oxirane. Tsunemoto Daiei et. al. and Kawamura Yasuo et al.494
synthesized oxirane derivatives (VII) which are useful as herbicides.
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CF3
N
S
O
R
O
O
O
NH
O
O
R
O OR
2
O
R
1
O
( VII) ( VIII) ( IX )
Janada Kim D.495 synthesised a series of novel oxirane derivatives. Which
are useful for inhibiting HIV-1 protease. Kaneko Masami et al.496 synthesized epoxy
cyclohexene dione (VIII) and reported as antibacterial and antitumor agent. Salqdino
Raffaele et al.497 prepared new 6-oxiranyl uracils which showed a potent and
selective antiviral activity against the Para influenza 1-virus replication. Tamogami
Shigeru et al.498 prepared epoxy cyclopentyl benzyl ether derivatives which possess
100% herbicidal activity against Echinochloa Crus-galli at 1ppm concentration.
Some epoxy keto furanosides (IX) have been reported as antitumor agents by
Kobayashi Shin et al.499 Further more, several derivatives of oxirane have been
patented for their use as antitumor500, antibacterial agents501, herbicides502, HIV-
protease503 inhibitors etc. Target compounds and intermediates were assayed for
anti-inflammatory effects on superoxide anion generation and elastase release by
human neutrophils in response to fMLP /CB, and for cytotoxic activity against
nasopharyngeal (KB), vincristine-resistant nasopharyngeal (KBvin), lung (A549) and
prostate (DU-145) human cancer cell lines.504
Led by this consideration several chalcone epoxides have been synthesised
and evaluated for their biological screening described as under.
Synthesis and therapeutic evaluation of (3-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)oxirane-2-yl) aryl methanone.
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SYNTHESIS AND THERAPEUTIC EVALUATION OF (3-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL) ARYL METHAN-
ONE.
The chemistry of oxiranes has assumed importance because of their
versatility in the synthesis of many heterocycles and polymeric compounds. Further
more, epoxides are also associated with spectrum of biological activities. Keeping
this in view, we have prepared some oxiranes compounds by the oxidation of
Chalcone using alkaline H2O2 shown as under.
Where,
R = Aryl
Where,
R= Aryl
N
N
R
O
CH3
Cl
N
N
R
O
CH3
Cl
O
Aq. NaOH
Methanol +
Acetone
30% H2O2
The structure elucidation of the synthesized compounds have been done on
the basis of elemental analyses, Infrared and 1H-nuclear magnetic resonance
spectroscopy and further supported by Mass spectroscopy.
The products have been evaluated for their in vitro antibacterial activity
towards Gram positive and Gram negative bacterial stains and antifungal activity
towards Aspergillus niger at a concentration of 40μg/ml. The biological activities of 
synthesized compounds were compared with standard drugs.
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REACTION SCHEME
N
N
Cl
CH3
R
O
R= Aryl
Where,
Aq.
NaOH Methanol+
Acetone
N
N
CH3
Cl
R
O
OWhere,
R= Aryl
N
N
Cl
CH3
CHO
R
CH3
O
10% KOH
30% H2O2
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IR SPECTRAL STUDIES OF (3-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL)(4-METHOXYPHENYL)METHAN-
ONE.
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Instrument : SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type Vibration Mode
Frequency in cm-1
Ref.
Observed Reported
Alkane C-H str.(asym.) 2925 2975-2950 143-a
-CH3 C-H str.(sym.) 2880 2880-2860 ”
C-H i.p.def 1450 1470-1435 ”
C-H o.o.p.def. 1386 1395-1370 ”
Aromatic C-H str. 3066 3090-3030 143-b
C=C Str. 1504 1520-1480 ”
C-H i.p.def 1116 1125-1090 ”
C-H o.o.p.def. 835 835-810 ”
Moiety C=N str. 1620 1610-1590 143-c
C-N str. 1190 1230-1020 ”
C-Cl str. 756 800-750 ”
C=O str. 1620 1700-1640 ”
Ether
(Epoxide)
C-O-C str. 825 865-785 143-d
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NMR SPECTRAL STUDIES OF (3-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL)(4-METHOXYPHENYL)METHAN-
ONE.
Internal Standard : TMS; Solvent : DMSO; Instrument : BRUKER Spectrometer
(400MHz)
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Signal
No.
Signal
Position
(δppm) 
Relative No.
of protons
Multiplicity Inference
1 2.50 3H singlet Ar-CH3
2 3.73 3H singlet Ar-OCH3
3 4.20 1H doublet CHh
4 3.50 1H doublet Ar-Hi
5 6.85 2H doublet Ar-H(a,a')
6 6.95 2H doublet Ar-H(b,b')
7 7.80 2H doublet Ar-H(f,f')
8 7.62 2H doublet Ar-H(g,g')
9 6.95 1H doublet Ar-Hc
10 7.90 1H doublet Ar-He
11 6.35 1H triplet Ar-Hd
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MASS SPECTRAL STUDIES OF (3-(2-(4-CHLOROPHENYL)-8-METHYL-1H-
IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL)(4-METHOXYPHENYL)METHAN-
ONE.
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EXPERIMENTAL
Synthesis and therapeutic evaluation of (3-(2-(4-chlorophenyl)-8-methyl-1H-
imidazo[1,2-a]pyridine-3-yl)oxirane-2-yl)(4-methoxyphenyl)methanone.
[A] Preparation of 2-chloro-1- (p-chlorophenyl)ethanone.
See on Page No. 37 Part-I (A)
[B] Preparation of 2-(p-chlorophenyl)- 8-methyl imidazo[1,2-a]pyridine
See on Page No. 37 Part-I (B)
[C] Preparation of 2-(p-chlorophenyl)- 8- methyl imidazo[1,2-a]pyridine- 3-
carbaldehyde.
See on Page No. 37 Part-I (C)
[D] Preparation of (2Z)-3-[2-(p-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine
- 3-yl]-1-aryl prop-2-en-1-one.
See on Page No. 38 Part-I (D)
[E] Preparation of (3-(2-(4-Chlorophenyl)-8-methyl-1H-imidazo[1,2-a]
pyridine-3-yl)oxirane-2-yl)(4-methoxyphenyl)methanone.
A mixture (2z)-3-[2-(4-chlorophenyl)-8-methyl imidazo[1,2-a]pyridine-3-yl]-1-
aryl prop-2-en-1-one (4.02gm,0.01m) and 30% H2O2 solution (0.34,0.01m) was
refluxed in Mixture of methanol and acetone for 1-2 hrs. Aq. NaOH solution is used
as catalyst. The contents were poured on to crushed ice and product isolated was
crystallized from di-chloromethane. Yield 60% (2.55gm); m.p.171 °C;(C24H19ClN2O3 ;
Found: C,68.75%;H,4.55%;N,6.60%; Required : C,68.82%;H,4.57%;N,,6.69%)
TLC solvent system : Ethyl acetate : Hexane ( 4:6)
Similarly, other Oxirane derivatives have been obtained. The physical data
are recorded in Table No.- 6(B).
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[F] Antimicrobial activity of (3-(2-(4-Chlorophenyl)-8-methyl-1H-imidazo
[1,2-a]pyridine-3-yl)oxirane-2-yl) aryl methanone.
Antimicrobial testing was carried out as described in part- I Experimental
Section [E] Page No. 38. The zone of inhibition of the test solution are recorded in
Table No.- 6(A).
TABLE NO.- 6(A) BIOLOGICAL SCREENING OF (3-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL) ARYL METHAN-
ONE.
Sr.
No.
R
Zone of inhibition in m.m
Antibacterial Antifungal
B.coccus S.aureus Pseudo
mona
E.coli A.niger
6a C6H5- 17 16 15 18 16
6b 4-CH3-C6H4 - 14 14 12 13 14
6c 4-OCH3 -C6H4- 13 12 13 14 13
6d 4-Cl-C6H4 - 18 15 17 16 19
6e 4-F-C6H4 - 14 13 14 12 12
6f 4-Br-C6H4 - 12 12 13 14 13
6g 4-NH2-C6H4 - 15 13 14 13 12
6h 4-NO2-C6H4 - 13 14 15 15 14
6i 4-OH-C6H4 - 15 19 16 16 17
Stdn Ampicillin 20 21 21 20 -
” Amoxicillin 22 21 22 22 -
” Ciprofloxacin 24 22 23 22 -
” Norfloxacin 23 23 23 23 -
” Greseofulvin - - - - 24
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TABLE NO.- 6(B) PHYSICAL CONSTANTS OF (3-(2-(4-CHLOROPHENYL)
-8-METHYL-1H-IMIDAZO[1,2-a]PYRIDINE-3-YL)OXIRANE-2-YL) ARYL METHAN-
ONE.
Sr.
No.
R
Molecular
Formula
M.W.
M.P.
°C
Rf*
Value
%
Yield
% Nitrogen
Calcd. Found
6a
6b
6c
6d
6e
6f
6g
6h
6i
C6H5 -
4-CH3-C6H4 -
4-OCH3-C6H4-
4-Cl-C6H4 -
4-F-C6H4 -
4-Br-C6H4 -
4-NH2-C6H4 -
4-NO2-C6H4 -
4-OH-C6H4 -
C23H17ClN2O2
C24H19ClN2O2
C24H19ClN2O3
C23H16Cl2N2O2
C23H16ClFN2O2
C23H16ClBrN2O2
C23H18ClN3O2
C23H16ClN3O4
C23H17ClN2O3
388.5
402.5
418.5
423.0
406.5
467.5
403.5
433.5
404.5
158.0
162.0
171.0
160.0
165.0
154.0
168.0
152.0
158.0
0.54
0.52
0.53
0.58
0.55
0.59
0.57
0.60
0.52
57.0
61.0
60.0
59.0
58.0
53.0
56.0
55.0
50.0
7.20
6.95
6.69
6.62
6.89
5.99
10.40
9.69
6.92
7.09
6.85
6.60
6.50
6.77
5.88
10.32
9.63
6.85
Solvent System : Ethyl acetate : Hexane (4:6)
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